<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/84915200-8B36-4D78-B908-BE6E8F42B272"><gtr:id>84915200-8B36-4D78-B908-BE6E8F42B272</gtr:id><gtr:name>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/839E5DAA-F3A9-4FCA-BC3A-A537F96D2C57"><gtr:id>839E5DAA-F3A9-4FCA-BC3A-A537F96D2C57</gtr:id><gtr:name>National Institute for Health and Care Excellence (NICE)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF"><gtr:id>F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF</gtr:id><gtr:name>Bangor University</gtr:name><gtr:address><gtr:line1>Bangor University</gtr:line1><gtr:line4>Bangor</gtr:line4><gtr:line5>Gwynedd</gtr:line5><gtr:postCode>LL57 2DG</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7254835D-A811-460C-ACFC-C345775924B4"><gtr:id>7254835D-A811-460C-ACFC-C345775924B4</gtr:id><gtr:name>The Cochrane Collaboration</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4A7D252-A2AA-4FB4-A88D-E15A159E9993"><gtr:id>F4A7D252-A2AA-4FB4-A88D-E15A159E9993</gtr:id><gtr:name>Hub at the MRC/CRUK/BHF Clinical Trial Service Unit</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A7D5F0-2767-4BED-A50A-595CA7E4B688"><gtr:id>A0A7D5F0-2767-4BED-A50A-595CA7E4B688</gtr:id><gtr:name>Department of Health (DH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C"><gtr:id>4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C</gtr:id><gtr:name>Birmingham Women's and Children's NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6726D03A-217B-461A-8939-2057211DF5A5"><gtr:id>6726D03A-217B-461A-8939-2057211DF5A5</gtr:id><gtr:name>MRC North West Hub for Trials Methodology Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADB14AFF-F6DF-4144-A743-0AAE3D33973D"><gtr:id>ADB14AFF-F6DF-4144-A743-0AAE3D33973D</gtr:id><gtr:name>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CBEBA2E5-F982-48DE-B88E-D505FB6F1492"><gtr:id>CBEBA2E5-F982-48DE-B88E-D505FB6F1492</gtr:id><gtr:name>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84915200-8B36-4D78-B908-BE6E8F42B272"><gtr:id>84915200-8B36-4D78-B908-BE6E8F42B272</gtr:id><gtr:name>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/839E5DAA-F3A9-4FCA-BC3A-A537F96D2C57"><gtr:id>839E5DAA-F3A9-4FCA-BC3A-A537F96D2C57</gtr:id><gtr:name>National Institute for Health and Care Excellence (NICE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF"><gtr:id>F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF</gtr:id><gtr:name>Bangor University</gtr:name><gtr:address><gtr:line1>Bangor University</gtr:line1><gtr:line4>Bangor</gtr:line4><gtr:line5>Gwynedd</gtr:line5><gtr:postCode>LL57 2DG</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7254835D-A811-460C-ACFC-C345775924B4"><gtr:id>7254835D-A811-460C-ACFC-C345775924B4</gtr:id><gtr:name>The Cochrane Collaboration</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4A7D252-A2AA-4FB4-A88D-E15A159E9993"><gtr:id>F4A7D252-A2AA-4FB4-A88D-E15A159E9993</gtr:id><gtr:name>Hub at the MRC/CRUK/BHF Clinical Trial Service Unit</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A7D5F0-2767-4BED-A50A-595CA7E4B688"><gtr:id>A0A7D5F0-2767-4BED-A50A-595CA7E4B688</gtr:id><gtr:name>Department of Health (DH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C"><gtr:id>4BCC4C8C-5B59-42E4-9E98-F60F7A4E0C2C</gtr:id><gtr:name>Birmingham Women's and Children's NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6EF3B963-88BD-4EA0-BDFE-60C742501F07"><gtr:id>6EF3B963-88BD-4EA0-BDFE-60C742501F07</gtr:id><gtr:name>Memorial Sloan Kettering Cancer Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6726D03A-217B-461A-8939-2057211DF5A5"><gtr:id>6726D03A-217B-461A-8939-2057211DF5A5</gtr:id><gtr:name>MRC North West Hub for Trials Methodology Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76119A17-D4F8-4258-80F0-C8B307FFFA52"><gtr:id>76119A17-D4F8-4258-80F0-C8B307FFFA52</gtr:id><gtr:name>Radboud University Nijmegen</gtr:name><gtr:address><gtr:line1>Radboud University Nijmegen</gtr:line1><gtr:line2>PO Box 9102</gtr:line2><gtr:line4>Nijmegen</gtr:line4><gtr:postCode>6500 HC</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC"><gtr:id>8A66BFC9-B9A5-48C6-B46C-761D1C13C5DC</gtr:id><gtr:name>Lancaster University</gtr:name><gtr:address><gtr:line1>,</gtr:line1><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_EX_G0800814"><gtr:id>C1DA8BE0-0EE1-4DEB-A6B0-FD78F0DFCFC4</gtr:id><gtr:title>MRC Clinical Trials Unit as the London Hub for Trials Methodology Research</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_EX_G0800814</gtr:grantReference><gtr:abstractText>Methodology is the science of how to do things. It underpins the design, conduct and analysis of clinical trials. The aim of this proposal is to improve this methodology, give better trials leading ultimately to better outcomes for patients.</gtr:abstractText><gtr:technicalSummary>The MRC CTU vision is to integrate methodological research within the development, execution, analysis and reporting of trials. The trials themselves pose methodological problems and in turn, the methodological work results in new and better ways of designing, conducting and analysing trials. Our methodological research will initially be focussed in areas where we already have established expertise and experience. We shall also respond to new methodological questions as they arise, and as time and priorities permit.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Organisation for Research and Treatment of Cancer (EORTC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>R39 Agreeing current good practice for clinical trial data access and sharing</gtr:description><gtr:id>9E963E7C-041D-4151-B021-CD86E00A8E8D</gtr:id><gtr:impact>Outputs include publication:DOI 10.1186/s12916-015-0532-z 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0532-z 

Also this has been highlighted in the Network Guidance pack. http://methodologyhubs.mrc.ac.uk/advice/network-guidance/ 

The guidance has been cited by various parties as of value including &amp;quot;This guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UK CRC Registered CTUs Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.&amp;quot;

Finally, the PI, together with colleagues within the Network have contributed to a publications from Springer Nature entitled &amp;quot; Publishing descriptions of non-public clinical datasets: guidance for researchers, repositories, editors and funding organizations&amp;quot;
Following a consultation, their comments have been used to revise these guidelines.</gtr:impact><gtr:outcomeId>E7rr4jsMXP2-6</gtr:outcomeId><gtr:partnerContribution>Network funding provided for project commencement</gtr:partnerContribution><gtr:piContribution>Network funded proposal- This proposal addresses a main priority area for the HTMR Network, that of using
existing evidence in the prioritisation, design and planning, conduct, and interpretation
of trials, all of which can be helped by improving access to clinical trial data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PRISMA-IPD Steering Group</gtr:description><gtr:id>D6849EF8-132B-4AC8-BFA9-08CF21A95B12</gtr:id><gtr:impact>Development of reporting guidelines and a checklist for the standardised reporting of systematic reviews and meta-anlayses of IPD</gtr:impact><gtr:outcomeId>545bb92bba4119.11922014-4</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution.</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution. Steering Group membership (Jayne Tierney)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bangor University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Methods for multiple imputation with multiple rating scales</gtr:description><gtr:id>5F2B972F-7CD3-4C0A-A563-B0CA60912D58</gtr:id><gtr:impact>No outputs yet to report as the collaboration is ongoing</gtr:impact><gtr:outcomeId>54575829bb0d37.55701323-1</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual input</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Stregthening the Analytical Thinking for Observational Studies: STRATOS initiatve</gtr:description><gtr:id>B089D05E-4D08-475F-98A6-330F39EC1BAC</gtr:id><gtr:impact>One paper has been published</gtr:impact><gtr:outcomeId>545b968e17a567.99977392-1</gtr:outcomeId><gtr:partnerContribution>Besides steering group membership, chair of the Topic Group on missing data, responsible for leading the activities of this group</gtr:partnerContribution><gtr:piContribution>Member of the steering committee (James Carpenter) and co-author of the paper in Statistics 
in Medicine which introduced this initiative</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Statistics</gtr:department><gtr:description>Oxford</gtr:description><gtr:id>34D2E5BF-8651-4AC2-BC31-66400405B23F</gtr:id><gtr:impact>Several papers including recently PUBMED 19477892, 19336487, 20641144</gtr:impact><gtr:outcomeId>p5WqU22RYb2-1</gtr:outcomeId><gtr:partnerContribution>Joint collaborative research</gtr:partnerContribution><gtr:piContribution>Joint collaborative research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hub at the MRC/CRUK/BHF Clinical Trial Service Unit</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>R39 Agreeing current good practice for clinical trial data access and sharing</gtr:description><gtr:id>EEBD5BAA-AF1A-48EB-BD25-77140FA5126A</gtr:id><gtr:impact>Outputs include publication:DOI 10.1186/s12916-015-0532-z 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0532-z 

Also this has been highlighted in the Network Guidance pack. http://methodologyhubs.mrc.ac.uk/advice/network-guidance/ 

The guidance has been cited by various parties as of value including &amp;quot;This guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UK CRC Registered CTUs Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.&amp;quot;

Finally, the PI, together with colleagues within the Network have contributed to a publications from Springer Nature entitled &amp;quot; Publishing descriptions of non-public clinical datasets: guidance for researchers, repositories, editors and funding organizations&amp;quot;
Following a consultation, their comments have been used to revise these guidelines.</gtr:impact><gtr:outcomeId>E7rr4jsMXP2-3</gtr:outcomeId><gtr:partnerContribution>Network funding provided for project commencement</gtr:partnerContribution><gtr:piContribution>Network funded proposal- This proposal addresses a main priority area for the HTMR Network, that of using
existing evidence in the prioritisation, design and planning, conduct, and interpretation
of trials, all of which can be helped by improving access to clinical trial data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Analysis of time to event IPD</gtr:description><gtr:id>A4914A0A-18C7-4B20-94FC-998059043EF4</gtr:id><gtr:impact>2 papers published</gtr:impact><gtr:outcomeId>RbAW1biQMSi-2</gtr:outcomeId><gtr:partnerContribution>Developed and ran simulations, analysed IPD, drafted one manucsript and contributed to another.Developed and ran simulations, analysed IPD, drafted one manuscript and contributed to another.</gtr:partnerContribution><gtr:piContribution>Responsible for develping and running simulations, analysing IPD and drafting a paper. Contributed to a related paper on methods of analyis of time to event IPD.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>B1- Big Idea- Adaptive Design Outreach officer</gtr:description><gtr:id>232D4A88-9F53-43F4-8D79-D09A8ACAA8BF</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>545a28e1a83d10.57759263-2</gtr:outcomeId><gtr:partnerContribution>This proposal is for an &amp;quot;Adaptive Design Outreach Officer&amp;quot; who would be associated with the Adaptive Designs Working Group (ADWG). The key aim would be to raise awareness and use of adaptive designs across a broad range of diseases and across the development and assessment spectrum. Adaptive methods in this context are defined in its broadest sense end will include Bayesian adaptive dose-finding and group-sequential methods, multi-arm trials, lack-of-benefit stopping rules and sample size reassessment methods. The main activity of the outreach officer would be to proactively engage with applied health researchers to discuss the merits and relative drawbacks of the currently available adaptive designs. In particular, the outreach officer would: 
1. Develop training material on current adaptive designs 
2. Visit each of the UKCRC registered Clinical Trials Units1 to present about the potential of adaptive designs 
3. Facilitate the uptake and implementation of adaptive designs 
4. Support the writing of tutorial papers on adaptive designs</gtr:partnerContribution><gtr:piContribution>Network funding provided for this post</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Reviews and Dissemination (CRD)</gtr:department><gtr:description>INVOLVE guidance for researchers on patient and public involvement in systematic reviews</gtr:description><gtr:id>43304708-1FB7-4A05-B168-3EA6A36E6C56</gtr:id><gtr:impact>Guidance published on INVOLVE website.</gtr:impact><gtr:outcomeId>moV5u991Rik-4</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Cochrane Collaboration</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Methodological Expectations of Cochrane Intervention Reviews: Searchng for Studies</gtr:description><gtr:id>DFA2F72C-84C3-4961-811C-F2EDE7AAB4A6</gtr:id><gtr:impact>Completed Methodological Expectations of Cochrane Intervention Reviews (MECIR) for searching for Studies.</gtr:impact><gtr:outcomeId>pzWu8K41Bad-1</gtr:outcomeId><gtr:partnerContribution>They will also help evaluate the recommendations outlined in the Cochrane Handbook and amend, adapt and build on these accordingly on (i) searching for studies for inclusion in systematic reviews and (ii) clear reporting of the search process and search strategies.</gtr:partnerContribution><gtr:piContribution>As a member ot the working group will help evaluate the recommendations outlined in the Cochrane Handbook and amend, adapt and build on these accordingly on (i) searching for studies for inclusion in systematic reviews and (ii) clear reporting of the search process and search strategies.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>Analysis of time to event IPD</gtr:description><gtr:id>49DD3891-B61A-4D1C-B3FC-AB261403CEE4</gtr:id><gtr:impact>2 papers published</gtr:impact><gtr:outcomeId>RbAW1biQMSi-1</gtr:outcomeId><gtr:partnerContribution>Developed and ran simulations, analysed IPD, drafted one manucsript and contributed to another.Developed and ran simulations, analysed IPD, drafted one manuscript and contributed to another.</gtr:partnerContribution><gtr:piContribution>Responsible for develping and running simulations, analysing IPD and drafting a paper. Contributed to a related paper on methods of analyis of time to event IPD.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC ConDuCT Trials Methodology Hub</gtr:department><gtr:description>R34 An ethnographic study of group decision making and member roles in TSC and TMG</gtr:description><gtr:id>9257E8B6-CE5C-4EEB-9494-BB7C4644B9E0</gtr:id><gtr:impact>Findings from the study have been successfully disseminated at a variety of conferences and 
workshops. These include: oral presentations at the MRC Trials Methodology Conference in Edinburgh (November 2013) and the South West Society for Academic Primary Care Conference in Bristol (March 2014). The study methods have been disseminated to the trials community through a Qualitative Research in Trials workshop at the University of Bristol (May 2013). A poster presentation was given at the Society for Clinical Trials in Philadelphia, USA (May 2014).

Publications have been submitted to Trials and await decision ( as Jan 2016)</gtr:impact><gtr:outcomeId>rMVsncsRymK-1</gtr:outcomeId><gtr:partnerContribution>Funding from the Network given.</gtr:partnerContribution><gtr:piContribution>Network funded project to work on An ethnographic
study of group decision-making and member roles to understand and improve how Trial
Steering Committees and Trial Management Groups contribute to trial conduct&amp;quot;</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Trials conduct methodology collaboration</gtr:description><gtr:id>3AFD1BDC-A48D-41D7-BD26-9CF75D55CF2F</gtr:id><gtr:impact>No outcomes to report as yet - collaboration still active</gtr:impact><gtr:outcomeId>5457771352d876.40719708-1</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution to push forward some specific areas of trial conduct methodoological research</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution to push forward some specific areas of trial conduct methodoological research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with AstraZeneca on cedaranib following ICON6 trial outcome</gtr:description><gtr:id>DCC1D6B0-3FD7-4F34-A2B1-D714F27F88B5</gtr:id><gtr:impact>Full study report in development</gtr:impact><gtr:outcomeId>546200ac855937.54748239-1</gtr:outcomeId><gtr:partnerContribution>Drug supply only until positive outcome of the study was reported. Subsequently, close colloaboration on preparation of regulatory package.</gtr:partnerContribution><gtr:piContribution>Sponsored and ran the ICON6 trial after AZ abandoned development of this compound. Now working with them to produce licensing application. Anticipate considerable research support plus drug supply for trials to follow.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute for Medical Biometry and Statistics</gtr:department><gtr:description>Freiburg</gtr:description><gtr:id>D916A491-19A4-42A0-8921-607C16905D2A</gtr:id><gtr:impact>Several papers, including recently PUBMED 20191601</gtr:impact><gtr:outcomeId>EoPYahADX6i-1</gtr:outcomeId><gtr:partnerContribution>Joint collaborative research</gtr:partnerContribution><gtr:piContribution>Joint collaborative research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>INVOLVE</gtr:department><gtr:description>INVOLVE guidance for researchers on patient and public involvement in systematic reviews</gtr:description><gtr:id>2E1AD57F-1467-4F30-84CD-9223842F1B95</gtr:id><gtr:impact>Guidance published on INVOLVE website.</gtr:impact><gtr:outcomeId>moV5u991Rik-5</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Causal Analyses in Translational Epidemiology</gtr:department><gtr:description>Using causal analyses to add value to large RCTs</gtr:description><gtr:id>DF2C9CAF-5547-426E-9A2B-0458EFE0A800</gtr:id><gtr:impact>Funding from the MRC Population and Health Sciences Network (to fund a cross-unit appointment for a joint appointment between CTU and CaiTE) commenced in April 2014 (until 2017)</gtr:impact><gtr:outcomeId>BoLFHD4mEYJ-1</gtr:outcomeId><gtr:partnerContribution>To help develop &amp;quot;best practice&amp;quot; examples to guide statisticians working in clinical academia in the use of causal methods
To help systematically survey the clinical literature, and ro conduct a scoping exercise to identify types of questions which causal models have most potential to answer in RCTs 
To help apply causal inference methods to use RCT data to answer two new clinical questions of different types
To help disseminate best practice through workshops,</gtr:partnerContribution><gtr:piContribution>To help develop &amp;quot;best practice&amp;quot; examples to guide statisticians working in clinical academia in the use of causal methods
To help systematically survey the clinical literature, and to conduct a scoping exercise to identify types of questions which causal models have most potential to answer in RCTs 
To help apply causal inference methods to use RCT data to answer two new clinical questions of different types
To help disseminate best practice through workshops,</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Making decisions at the end of a Phase 2 clinical trial</gtr:description><gtr:id>1BD2238D-6B10-46C5-952E-D436976F3753</gtr:id><gtr:impact>2 research papers published and a further paper has been submitted; has had implications for how trial design decisions are made within Amgen</gtr:impact><gtr:outcomeId>56d6bc1998d790.96750494-1</gtr:outcomeId><gtr:partnerContribution>Methodological development and simulation work as part of a PhD research project</gtr:partnerContribution><gtr:piContribution>Methodological development of an approach to the decision as to whether to proceed to a phase three trial at the end of phase two that synthesizes the available data. An exploration as to how this can also be used to design trials at phase two and three.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Clatterbridge Cancer Centre NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MAMS design for ocular melanoma</gtr:description><gtr:id>B23098E7-3FD3-4417-8AE2-86DDEEF404C2</gtr:id><gtr:impact>Two grant applications have been submitted. The first, to NCI CTEP, was not successful. A small trial will be undertaken which will be led from the US. MRC CTU did not wish to be involved with the specific design. Could return to the table for future discussions. Convinced the group that a multi-arm trial was appropriate.</gtr:impact><gtr:outcomeId>YYLApMPmhcm-1</gtr:outcomeId><gtr:partnerContribution>Leadership of research, discussion with CTEP and other organisations.</gtr:partnerContribution><gtr:piContribution>Development of potential designs to assess a number of agents simultaneously in clinical trial of treatment for relapsed ocular melanoma, a rare but rapidly fatal condition. Multi-arm multi-stage trials were dicussed and chosen as the design.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Evidence Synthesis Working Group</gtr:description><gtr:id>2EA9CD32-171E-4258-BA68-BD3BE60DC717</gtr:id><gtr:impact>Ongoing activities. Hosting a session as part of the HTMR annual meeting</gtr:impact><gtr:outcomeId>545a190bf34e74.00186386-1</gtr:outcomeId><gtr:partnerContribution>Scope- The Evidence Synthesis Working Group focuses on the use of evidence synthesis, or systematic reviews, in the design, monitoring and interpretation of trials.
 
Future Objectives- The Working Group is preparing a series of papers to help trialists and others to make best use of evidence synthesis, including those based on the central collection and re-analysis of participant level data. It will develop clear recommendations for how evidence synthesis can be used in the design, conduct, and analysis of trials with a view to increasing the use of these methods in practice and reducing the waste in research that can arise when proper notice is not paid to existing evidence. &amp;quot;Position papers&amp;quot; will bring together work on the use of evidence synthesis in trial design, conduct and analysis in general, and compare methods for using evidence synthesis when estimating sample size requirements for new trials, using the Corticosteroid Randomisation After Significant Head injury (CRASH) trial as a worked example.
 
Members of the Working Group are also collaborating to adapt the established principles for systematic reviews of trials to apply them elsewhere in the process of translational research, including within animal studies, evaluations of diagnostic tests and of prognostic models, and research to identify biomarkers and surrogate endpoints that might be used in trials.</gtr:partnerContribution><gtr:piContribution>The HTMR Network supports the Evidence Synthesis Working Group (WG) to regularly meet and exchange ideas. This involves members of the methodology community and Hub members.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Adaptive Designs Working Group</gtr:description><gtr:id>D0E93789-06E6-4AB6-8E8B-BD46AC64D746</gtr:id><gtr:impact>Adaptive designs meet regularly and host an annual meeting on their research.

There is an adaptive design outreach officer - paid for by the Network- who is undertaking regular visits to CTUs and is working on new research methodologies. To date (2016 Feb) 7 CTUs have been visited, and they have collaborated with one group on developing a trial application</gtr:impact><gtr:outcomeId>56d6b79c6b25b5.03625074-1</gtr:outcomeId><gtr:partnerContribution>Scope: The Adaptive Designs Working Group collaborates to increase uptake of methods, to improve knowledge and to link with key stakeholders such as regulators and industry in this important area for improving the speed and efficiency of trials. Future objectives: The Network plays a vital role in increasing the implementation of adaptive design methodology, with the main barriers to implementation already identified as a lack of software and a lack of expertise. The future plans for this group include continued annual meetings, strengthening the engagement with industry and the development of collaborative inter-Hub visits to develop novel adaptive designs. The group is focusing its efforts on preparing tutorial papers for applied journals and mainstream medical journals; presentations and lectures to increase uptake of methods among stakeholders; and the development of computer software to help researchers to undertake trials with adaptive designs.</gtr:partnerContribution><gtr:piContribution>The HTMR Network supported the Adaptive Designs Working Group (WG) to regularly meet and exchange ideas. This involves members of the methodology community and Hub members.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Reviews and Dissemination (CRD)</gtr:department><gtr:description>R20 Workshop and guidance on IPD meta-analysis</gtr:description><gtr:id>4442C378-5520-487A-88CE-DF799D03E8B7</gtr:id><gtr:impact>publications:
25747860; 26186982; 26196287</gtr:impact><gtr:outcomeId>A5MDo4atn3J-1</gtr:outcomeId><gtr:partnerContribution>Helping develop the funding proposal, project planning, developing the workshop. Drafting and reviewing subsequent IPD guidance papers.</gtr:partnerContribution><gtr:piContribution>HTMR Network funded the project.

MRC CTU London Hub- Leading the development of the funding proposal, project planning and organising, developing and running the workshop. Drafting and reviewing subsequenIPD t guidance papers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stepped wedge trial design</gtr:description><gtr:id>B7083313-37FC-4690-ABDF-6658119ADF37</gtr:id><gtr:impact>Special issue of Trials (6 articles), workshop to present the findings. Further collaboration with other parts of UCL as well as with LSHTM. Work is already being cited.</gtr:impact><gtr:outcomeId>56d84633c3a129.37643224-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions</gtr:partnerContribution><gtr:piContribution>Intellectual contribution to all activities, lead authorship on one of 6 publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre of Evidence Based Dermatology</gtr:department><gtr:description>MAMS design for erosive lichen planus</gtr:description><gtr:id>9E71FDA3-E594-43C0-B289-0500168EBD01</gtr:id><gtr:impact>Grant applications submitted to NIHR and RfPB. Lead researcher has successfully won an NIHR fellowship during this time to contribute further to the research.</gtr:impact><gtr:outcomeId>56d6b95695bae4.00276972-1</gtr:outcomeId><gtr:partnerContribution>Treatment of patients, design and discussion and leadership of research.</gtr:partnerContribution><gtr:piContribution>Group keen to develop a methodologically efficient design to assess new treatments for women with vulval erosive lichen planus, a rare but debilitating condition. We have worked to help develop study designs, including updates to the multi-arm multi-stage approach, which will be covered in a PhD (Dan B). Eventually calculated that a multi-stage approach could not be used with the particular outcome measures required for the condition. Funding was successfully obtained for the trial which will be run from Nottingham CTU. MRC CTU's Scientific Strategy Group chose not to proceed with this. The unit has developed the first draft of the Statistical Analysis Plan and will engage in an advisory capacity. One member of the unit will serve on the IDMC.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC North West Hub for Trials Methodology Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>R20 Workshop and guidance on IPD meta-analysis</gtr:description><gtr:id>6C654703-45E8-4B8C-ADD7-BFEBDB0CA74E</gtr:id><gtr:impact>publications:
25747860; 26186982; 26196287</gtr:impact><gtr:outcomeId>A5MDo4atn3J-4</gtr:outcomeId><gtr:partnerContribution>Helping develop the funding proposal, project planning, developing the workshop. Drafting and reviewing subsequent IPD guidance papers.</gtr:partnerContribution><gtr:piContribution>HTMR Network funded the project.

MRC CTU London Hub- Leading the development of the funding proposal, project planning and organising, developing and running the workshop. Drafting and reviewing subsequenIPD t guidance papers</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Cochrane Collaboration</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>INVOLVE guidance for researchers on patient and public involvement in systematic reviews</gtr:description><gtr:id>A7828951-A8BA-4A66-8617-EEB2D5395F2A</gtr:id><gtr:impact>Guidance published on INVOLVE website.</gtr:impact><gtr:outcomeId>moV5u991Rik-1</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Re-randomisation of patients to a clinical trial</gtr:description><gtr:id>02A9D19A-5977-4832-A42E-4725AD69A883</gtr:id><gtr:impact>Several invited seminars (Leeds, Leicester, LSHTM), conference papers, one published paper.</gtr:impact><gtr:outcomeId>56d6b9eedfabb7.17819060-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design.</gtr:partnerContribution><gtr:piContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Health (DH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC/DH/MHRA Joint Project</gtr:description><gtr:id>8556D78B-6CDC-4A5A-9C01-D74E50D6698C</gtr:id><gtr:impact>Guidance document (on MHRA website Oct 2011) &amp;quot;Risk-adapted approaches to the management of clinical trials of investigational medicinal products&amp;quot; incorporating guidance on risk adapted approaches within the scope of the Clinical Trials Directive and Guidance on risk-proportionate approaches to the management and monitoring of clinical trials.
The collaboration is multi-disciplinary developed with input from a wide range of stakeholders including academic researchers, clinical trial managers, research governance managers, MHRA assessors and Good Clinical Practice Inspectors</gtr:impact><gtr:outcomeId>nRBWHmCtW19-1</gtr:outcomeId><gtr:partnerContribution>Input to the development of a risk stratification project as member of an ad hoc working group</gtr:partnerContribution><gtr:piContribution>Input to the development of a risk stratification project as member of an ad hoc working group and co-chair of risk-stratification sub-group</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Midland Hub for Trials Methodology Research (MHTMR)</gtr:department><gtr:description>R20 Workshop and guidance on IPD meta-analysis</gtr:description><gtr:id>03AAF087-B789-4CC8-B4DA-6C52D0BDAC7A</gtr:id><gtr:impact>publications:
25747860; 26186982; 26196287</gtr:impact><gtr:outcomeId>A5MDo4atn3J-5</gtr:outcomeId><gtr:partnerContribution>Helping develop the funding proposal, project planning, developing the workshop. Drafting and reviewing subsequent IPD guidance papers.</gtr:partnerContribution><gtr:piContribution>HTMR Network funded the project.

MRC CTU London Hub- Leading the development of the funding proposal, project planning and organising, developing and running the workshop. Drafting and reviewing subsequenIPD t guidance papers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health and Care Excellence (NICE)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>INVOLVE guidance for researchers on patient and public involvement in systematic reviews</gtr:description><gtr:id>0535AF40-6CE3-4696-9A03-2436913D0D5F</gtr:id><gtr:impact>Guidance published on INVOLVE website.</gtr:impact><gtr:outcomeId>moV5u991Rik-2</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Methodology Research Collaboration with industry</gtr:description><gtr:id>0B84E493-313D-48F3-A094-797298D2A953</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>56d6bdc221c2c3.85148695-1</gtr:outcomeId><gtr:partnerContribution>Commitment to developing research activity in to design, conduct or analysis methodology in areas of mutual interest. Detailed discussions ongoing</gtr:partnerContribution><gtr:piContribution>Commitment to developing research activity in to design, conduct or analysis methodology in areas of mutual interest. Detailed discussions ongoing</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Leeds Clinical Trials Unit</gtr:department><gtr:description>INVOLVE guidance for researchers on patient and public involvement in clinical trials</gtr:description><gtr:id>25755C68-2870-4B55-8309-23A8EE8EF75F</gtr:id><gtr:impact>Guidance published on submited INVOLVE website..</gtr:impact><gtr:outcomeId>Hq79cGK8M8Z-3</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PRISMA-IPD Steering Group</gtr:description><gtr:id>DA714C8D-2576-4A5B-9CBE-3CAD9879A36B</gtr:id><gtr:impact>Development of reporting guidelines and a checklist for the standardised reporting of systematic reviews and meta-anlayses of IPD</gtr:impact><gtr:outcomeId>545bb92bba4119.11922014-1</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution.</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution. Steering Group membership (Jayne Tierney)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Trials conduct methodology collaboration</gtr:description><gtr:id>7959E4CB-ED30-413E-8730-4A60AAF79F76</gtr:id><gtr:impact>No outcomes to report as yet - collaboration still active</gtr:impact><gtr:outcomeId>5457771352d876.40719708-3</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution to push forward some specific areas of trial conduct methodoological research</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution to push forward some specific areas of trial conduct methodoological research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wales Cancer Trials Unit</gtr:department><gtr:description>INVOLVE guidance for researchers on patient and public involvement in clinical trials</gtr:description><gtr:id>49BCCF0E-F58B-4CE0-9429-9F3CB69AF191</gtr:id><gtr:impact>Guidance published on submited INVOLVE website..</gtr:impact><gtr:outcomeId>Hq79cGK8M8Z-1</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The All-Ireland Hub for Trials Methodology Research</gtr:department><gtr:description>R20 Workshop and guidance on IPD meta-analysis</gtr:description><gtr:id>0C1640B8-4231-46AA-B7CA-F7AF36B28B0E</gtr:id><gtr:impact>publications:
25747860; 26186982; 26196287</gtr:impact><gtr:outcomeId>A5MDo4atn3J-2</gtr:outcomeId><gtr:partnerContribution>Helping develop the funding proposal, project planning, developing the workshop. Drafting and reviewing subsequent IPD guidance papers.</gtr:partnerContribution><gtr:piContribution>HTMR Network funded the project.

MRC CTU London Hub- Leading the development of the funding proposal, project planning and organising, developing and running the workshop. Drafting and reviewing subsequenIPD t guidance papers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Clustering and covariates in the design and analysis of RCTs</gtr:description><gtr:id>9CBB7640-5E48-4138-AC6F-A55E8D7CF496</gtr:id><gtr:impact>A number of publications have resulted from this collaboration:
PMID: 23825027, 24749914, 24755011, 24456267</gtr:impact><gtr:outcomeId>54576bedefc4d8.84958870-1</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual input</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Multiple imputation by predictive mean matching using multilevel models</gtr:description><gtr:id>51013180-BA4F-4B80-B1C4-E7CF6C4BDCEC</gtr:id><gtr:impact>No outputs yet to report, collaboration still active. Manuscript submitted for publication - currently under review (Nov 2014)</gtr:impact><gtr:outcomeId>54575a460ec3b9.35664991-1</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual input</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual input</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>R20 Workshop and guidance on IPD meta-analysis</gtr:description><gtr:id>03CDC7E9-EA48-4FF1-80A2-9633014EBB6F</gtr:id><gtr:impact>publications:
25747860; 26186982; 26196287</gtr:impact><gtr:outcomeId>A5MDo4atn3J-3</gtr:outcomeId><gtr:partnerContribution>Helping develop the funding proposal, project planning, developing the workshop. Drafting and reviewing subsequent IPD guidance papers.</gtr:partnerContribution><gtr:piContribution>HTMR Network funded the project.

MRC CTU London Hub- Leading the development of the funding proposal, project planning and organising, developing and running the workshop. Drafting and reviewing subsequenIPD t guidance papers</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Memorial Sloan Kettering Cancer Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MAMS design for ocular melanoma</gtr:description><gtr:id>1ED200BA-A5CD-4A6D-8D47-45C0D0EC76F4</gtr:id><gtr:impact>Two grant applications have been submitted. The first, to NCI CTEP, was not successful. A small trial will be undertaken which will be led from the US. MRC CTU did not wish to be involved with the specific design. Could return to the table for future discussions. Convinced the group that a multi-arm trial was appropriate.</gtr:impact><gtr:outcomeId>YYLApMPmhcm-2</gtr:outcomeId><gtr:partnerContribution>Leadership of research, discussion with CTEP and other organisations.</gtr:partnerContribution><gtr:piContribution>Development of potential designs to assess a number of agents simultaneously in clinical trial of treatment for relapsed ocular melanoma, a rare but rapidly fatal condition. Multi-arm multi-stage trials were dicussed and chosen as the design.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Molecular Medical Sciences Nottingham</gtr:department><gtr:description>MAMS design for ocular melanoma</gtr:description><gtr:id>1105ED4C-5FC9-4AE0-AACB-489AF1A1D63D</gtr:id><gtr:impact>Two grant applications have been submitted. The first, to NCI CTEP, was not successful. A small trial will be undertaken which will be led from the US. MRC CTU did not wish to be involved with the specific design. Could return to the table for future discussions. Convinced the group that a multi-arm trial was appropriate.</gtr:impact><gtr:outcomeId>YYLApMPmhcm-3</gtr:outcomeId><gtr:partnerContribution>Leadership of research, discussion with CTEP and other organisations.</gtr:partnerContribution><gtr:piContribution>Development of potential designs to assess a number of agents simultaneously in clinical trial of treatment for relapsed ocular melanoma, a rare but rapidly fatal condition. Multi-arm multi-stage trials were dicussed and chosen as the design.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>INVOLVE</gtr:department><gtr:description>INVOLVE guidance for researchers on patient and public involvement in clinical trials</gtr:description><gtr:id>16CE6057-6437-4D8D-B758-02204617F8FF</gtr:id><gtr:impact>Guidance published on submited INVOLVE website..</gtr:impact><gtr:outcomeId>Hq79cGK8M8Z-4</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sample size calculations for cluster randomised trials</gtr:description><gtr:id>7421E3D0-2F4E-4408-93C1-51D46B335057</gtr:id><gtr:impact>Two research papers have been published and a presentation has been made at a conference. One further article is in development</gtr:impact><gtr:outcomeId>56d6bb97c0dd01.70370334-1</gtr:outcomeId><gtr:partnerContribution>Joint supervision of PhD student</gtr:partnerContribution><gtr:piContribution>Review of how sample size calculations are made and reported in cluster randomised trials, critical review of the published sample formulae with practical guidance. Further work will include development of guidance for calculating sample size for trials with an ordinal outcome</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>PRISMA-IPD Steering Group</gtr:description><gtr:id>5603E5B9-88D4-4F82-B166-F779B841A8EE</gtr:id><gtr:impact>Development of reporting guidelines and a checklist for the standardised reporting of systematic reviews and meta-anlayses of IPD</gtr:impact><gtr:outcomeId>545bb92bba4119.11922014-3</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution.</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution. Steering Group membership (Jayne Tierney)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC North West Hub for Trials Methodology Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>R39 Agreeing current good practice for clinical trial data access and sharing</gtr:description><gtr:id>E598CDA6-7CB0-472C-9E6F-892095CC1C83</gtr:id><gtr:impact>Outputs include publication:DOI 10.1186/s12916-015-0532-z 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0532-z 

Also this has been highlighted in the Network Guidance pack. http://methodologyhubs.mrc.ac.uk/advice/network-guidance/ 

The guidance has been cited by various parties as of value including &amp;quot;This guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UK CRC Registered CTUs Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.&amp;quot;

Finally, the PI, together with colleagues within the Network have contributed to a publications from Springer Nature entitled &amp;quot; Publishing descriptions of non-public clinical datasets: guidance for researchers, repositories, editors and funding organizations&amp;quot;
Following a consultation, their comments have been used to revise these guidelines.</gtr:impact><gtr:outcomeId>E7rr4jsMXP2-1</gtr:outcomeId><gtr:partnerContribution>Network funding provided for project commencement</gtr:partnerContribution><gtr:piContribution>Network funded proposal- This proposal addresses a main priority area for the HTMR Network, that of using
existing evidence in the prioritisation, design and planning, conduct, and interpretation
of trials, all of which can be helped by improving access to clinical trial data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Re-randomisation of patients to a clinical trial</gtr:description><gtr:id>66FB11A3-F804-443F-97F9-A6D879D523B3</gtr:id><gtr:impact>Several invited seminars (Leeds, Leicester, LSHTM), conference papers, one published paper.</gtr:impact><gtr:outcomeId>56d6b9eedfabb7.17819060-2</gtr:outcomeId><gtr:partnerContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design.</gtr:partnerContribution><gtr:piContribution>Intellectual input to original design and resulting paper; currently working on follow up projects to demonstrate strengths and weaknesses and to understand practicalities of the design</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC General Practice Research Framework</gtr:department><gtr:description>Strategies to reduce attrition</gtr:description><gtr:id>CE9F4052-0BEA-484D-AA6E-4DDC41FD8963</gtr:id><gtr:impact>For the systematic review, 1 published protocol and 2 presentations international and 2 presentations at national conferences. For the qualitative review 3 presentations at national conferences.

This is a multidisciplinary collaboration including clinicians, IPD meta analysis experts, statisticians and qualitative researchers.</gtr:impact><gtr:outcomeId>Lf9AgTxNnW2-1</gtr:outcomeId><gtr:partnerContribution>Involved in all aspects of the design and conduct of both a systematic review and qualitative review of strategies to reduce attrition from randomised trials.</gtr:partnerContribution><gtr:piContribution>Key role in protocol development, searching for trials, data extraction, analysis and interpretation for a systematic review of strategies to reduce attrition from trials. Involved in the development of the protocol and structured interviews and the thematic anaylsis of interview transcripts for a qualitative review of trial investigators, trial mangers and research nurses views on strategies to reduce attrition from trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Women's and Children's NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel clinical trial design in a surgical setting (ROSSINI II)</gtr:description><gtr:id>64B4B001-1BBA-4FD0-8AE9-ACC53EC96C4E</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>56d6bb13dfd4b5.95248674-1</gtr:outcomeId><gtr:partnerContribution>Responsible for submitting the funding application and running the clinical trial</gtr:partnerContribution><gtr:piContribution>Key role in the trial design and sample size calculation. Developed a proposal for the design of the trial, using novel multi-arm multi-stage design, with binary outcome (total: eight arms).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Health Sciences</gtr:department><gtr:description>Leicester</gtr:description><gtr:id>BEEFD27E-355B-4427-AF9C-8CE2FBF3DBFC</gtr:id><gtr:impact>Several papers, including those in Stata Journal, and recently PUBMED 20213719</gtr:impact><gtr:outcomeId>Eqem5UbxB2R-1</gtr:outcomeId><gtr:partnerContribution>Joint collaborative research</gtr:partnerContribution><gtr:piContribution>Joint collaborative research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC/DH/MHRA Joint Project</gtr:description><gtr:id>B5B1500A-5907-404F-81F0-5C9E17F5063A</gtr:id><gtr:impact>Guidance document (on MHRA website Oct 2011) &amp;quot;Risk-adapted approaches to the management of clinical trials of investigational medicinal products&amp;quot; incorporating guidance on risk adapted approaches within the scope of the Clinical Trials Directive and Guidance on risk-proportionate approaches to the management and monitoring of clinical trials.
The collaboration is multi-disciplinary developed with input from a wide range of stakeholders including academic researchers, clinical trial managers, research governance managers, MHRA assessors and Good Clinical Practice Inspectors</gtr:impact><gtr:outcomeId>nRBWHmCtW19-2</gtr:outcomeId><gtr:partnerContribution>Input to the development of a risk stratification project as member of an ad hoc working group</gtr:partnerContribution><gtr:piContribution>Input to the development of a risk stratification project as member of an ad hoc working group and co-chair of risk-stratification sub-group</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>INVOLVE guidance for researchers on patient and public involvement in systematic reviews</gtr:description><gtr:id>18DDDB60-E993-4B31-A6CC-BBAB2CAF3E61</gtr:id><gtr:impact>Guidance published on INVOLVE website.</gtr:impact><gtr:outcomeId>moV5u991Rik-3</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in systematic reviews for the INVOLVE website</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Midland Hub for Trials Methodology Research (MHTMR)</gtr:department><gtr:description>R39 Agreeing current good practice for clinical trial data access and sharing</gtr:description><gtr:id>2C0BA3CB-3946-47A6-9904-8D504E8DCE94</gtr:id><gtr:impact>Outputs include publication:DOI 10.1186/s12916-015-0532-z 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0532-z 

Also this has been highlighted in the Network Guidance pack. http://methodologyhubs.mrc.ac.uk/advice/network-guidance/ 

The guidance has been cited by various parties as of value including &amp;quot;This guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UK CRC Registered CTUs Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.&amp;quot;

Finally, the PI, together with colleagues within the Network have contributed to a publications from Springer Nature entitled &amp;quot; Publishing descriptions of non-public clinical datasets: guidance for researchers, repositories, editors and funding organizations&amp;quot;
Following a consultation, their comments have been used to revise these guidelines.</gtr:impact><gtr:outcomeId>E7rr4jsMXP2-5</gtr:outcomeId><gtr:partnerContribution>Network funding provided for project commencement</gtr:partnerContribution><gtr:piContribution>Network funded proposal- This proposal addresses a main priority area for the HTMR Network, that of using
existing evidence in the prioritisation, design and planning, conduct, and interpretation
of trials, all of which can be helped by improving access to clinical trial data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Edinburgh Hub for Trials Methodology Research</gtr:department><gtr:description>R39 Agreeing current good practice for clinical trial data access and sharing</gtr:description><gtr:id>20674A33-85B1-4FB4-A6FE-3B66ACA765C9</gtr:id><gtr:impact>Outputs include publication:DOI 10.1186/s12916-015-0532-z 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0532-z 

Also this has been highlighted in the Network Guidance pack. http://methodologyhubs.mrc.ac.uk/advice/network-guidance/ 

The guidance has been cited by various parties as of value including &amp;quot;This guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UK CRC Registered CTUs Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.&amp;quot;

Finally, the PI, together with colleagues within the Network have contributed to a publications from Springer Nature entitled &amp;quot; Publishing descriptions of non-public clinical datasets: guidance for researchers, repositories, editors and funding organizations&amp;quot;
Following a consultation, their comments have been used to revise these guidelines.</gtr:impact><gtr:outcomeId>E7rr4jsMXP2-4</gtr:outcomeId><gtr:partnerContribution>Network funding provided for project commencement</gtr:partnerContribution><gtr:piContribution>Network funded proposal- This proposal addresses a main priority area for the HTMR Network, that of using
existing evidence in the prioritisation, design and planning, conduct, and interpretation
of trials, all of which can be helped by improving access to clinical trial data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Biostatistics Unit</gtr:department><gtr:description>MRC BSU</gtr:description><gtr:id>C48E61F6-0770-4D6A-9B30-38B29479C4ED</gtr:id><gtr:impact>Several papers including recently PUBMED 19153970, 19452569, 21225900</gtr:impact><gtr:outcomeId>E6xqCa6NVrP-1</gtr:outcomeId><gtr:partnerContribution>Joint collaborative research</gtr:partnerContribution><gtr:piContribution>Joint collaborative research</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Stratified Medicine WG</gtr:description><gtr:id>203F08A4-56EB-4984-A3BB-5A94A270683C</gtr:id><gtr:impact>ongoing collaborations.</gtr:impact><gtr:outcomeId>545a1aa4ed8e65.77288952-1</gtr:outcomeId><gtr:partnerContribution>Scope- Stratified Medicine is about tailoring treatments to specific patients, helping to ensure the highest chance of benefit and minimising the potential for harm or unnecessary treatment
 
The Stratified Medicine Working Group collaborates to look at novel designs for biomarker-stratified trials, and to bring the stratified medicine approach into a wider range of disease areas, complementing work already done in the widely studied examples of cancer and heart disease.
 
Future Objectives- The Working Group is preparing a guidance paper to help people reading a stratified medicine research paper, and has started to explore means for delivering advice to applicants to the MRC Research Panel on Stratified Medicine. Members of the Working Group are also planning to develop prognostic models that help in the prediction of harms and benefits following the use of thrombolysis to treat stroke, drawing on individual participant data meta-analysis of clinical trials.</gtr:partnerContribution><gtr:piContribution>The HTMR Network supports the Stratified Medicine Working Group (WG) to regularly meet and exchange ideas. This involves members of the methodology community and Hub members.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Trials conduct methodology collaboration</gtr:description><gtr:id>EE57345C-2FC1-4A5B-8138-880112D9523A</gtr:id><gtr:impact>No outcomes to report as yet - collaboration still active</gtr:impact><gtr:outcomeId>5457771352d876.40719708-2</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution to push forward some specific areas of trial conduct methodoological research</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution to push forward some specific areas of trial conduct methodoological research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Trials Unit</gtr:department><gtr:description>B1- Big Idea- Adaptive Design Outreach officer</gtr:description><gtr:id>BEB315DC-F6D7-4096-8FD2-CC226863C3E8</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>545a28e1a83d10.57759263-3</gtr:outcomeId><gtr:partnerContribution>This proposal is for an &amp;quot;Adaptive Design Outreach Officer&amp;quot; who would be associated with the Adaptive Designs Working Group (ADWG). The key aim would be to raise awareness and use of adaptive designs across a broad range of diseases and across the development and assessment spectrum. Adaptive methods in this context are defined in its broadest sense end will include Bayesian adaptive dose-finding and group-sequential methods, multi-arm trials, lack-of-benefit stopping rules and sample size reassessment methods. The main activity of the outreach officer would be to proactively engage with applied health researchers to discuss the merits and relative drawbacks of the currently available adaptive designs. In particular, the outreach officer would: 
1. Develop training material on current adaptive designs 
2. Visit each of the UKCRC registered Clinical Trials Units1 to present about the potential of adaptive designs 
3. Facilitate the uptake and implementation of adaptive designs 
4. Support the writing of tutorial papers on adaptive designs</gtr:partnerContribution><gtr:piContribution>Network funding provided for this post</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lancaster University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>B1- Big Idea- Adaptive Design Outreach officer</gtr:description><gtr:id>22E2A662-3576-48CA-AD4C-4F19C29DDC65</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>545a28e1a83d10.57759263-1</gtr:outcomeId><gtr:partnerContribution>This proposal is for an &amp;quot;Adaptive Design Outreach Officer&amp;quot; who would be associated with the Adaptive Designs Working Group (ADWG). The key aim would be to raise awareness and use of adaptive designs across a broad range of diseases and across the development and assessment spectrum. Adaptive methods in this context are defined in its broadest sense end will include Bayesian adaptive dose-finding and group-sequential methods, multi-arm trials, lack-of-benefit stopping rules and sample size reassessment methods. The main activity of the outreach officer would be to proactively engage with applied health researchers to discuss the merits and relative drawbacks of the currently available adaptive designs. In particular, the outreach officer would: 
1. Develop training material on current adaptive designs 
2. Visit each of the UKCRC registered Clinical Trials Units1 to present about the potential of adaptive designs 
3. Facilitate the uptake and implementation of adaptive designs 
4. Support the writing of tutorial papers on adaptive designs</gtr:partnerContribution><gtr:piContribution>Network funding provided for this post</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>INVOLVE guidance for researchers on patient and public involvement in clinical trials</gtr:description><gtr:id>17E5F3BB-BF0E-4E7F-8E27-A196BB45D1BA</gtr:id><gtr:impact>Guidance published on submited INVOLVE website..</gtr:impact><gtr:outcomeId>Hq79cGK8M8Z-2</gtr:outcomeId><gtr:partnerContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website.Helped draft guidance on patient and public involvement in trials for the INVOLVE website Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:partnerContribution><gtr:piContribution>Helped draft guidance on patient and public involvement in trials for the INVOLVE website</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PRISMA-IPD Steering Group</gtr:description><gtr:id>5655841A-86B2-4497-B9D5-F78A6518B84F</gtr:id><gtr:impact>Development of reporting guidelines and a checklist for the standardised reporting of systematic reviews and meta-anlayses of IPD</gtr:impact><gtr:outcomeId>545bb92bba4119.11922014-2</gtr:outcomeId><gtr:partnerContribution>Expertise and intellectual contribution.</gtr:partnerContribution><gtr:piContribution>Expertise and intellectual contribution. Steering Group membership (Jayne Tierney)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NIHR Evaluation, Trials and Studies Coordinating Centre</gtr:department><gtr:description>R25- Remits, roles and working models for Trial Steering Committees and Data Monitoring Committees in clinical trials evaluating diagnostic tests, most notably test accuracy studies.</gtr:description><gtr:id>5D7DA3A9-8C33-4649-98B0-430F50B7B49B</gtr:id><gtr:impact>Review, workshop and expert consensus expected. Collaborative work only just begun</gtr:impact><gtr:outcomeId>FCWM1LTBDQj-1</gtr:outcomeId><gtr:partnerContribution>Review, workshop and expert consensus expected in 2015</gtr:partnerContribution><gtr:piContribution>Network support- funding provided for this project- links in with a suite of Network research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Hubs for Trial Methodology Research</gtr:department><gtr:description>R39 Agreeing current good practice for clinical trial data access and sharing</gtr:description><gtr:id>F4496538-F0B4-4BDF-B206-330AEF9995FD</gtr:id><gtr:impact>Outputs include publication:DOI 10.1186/s12916-015-0532-z 
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0532-z 

Also this has been highlighted in the Network Guidance pack. http://methodologyhubs.mrc.ac.uk/advice/network-guidance/ 

The guidance has been cited by various parties as of value including &amp;quot;This guidance has been endorsed by Cancer Research UK, MRC Methodology Research Programme Advisory Group, Wellcome Trust and the Executive Group of the UK CRC Registered CTUs Network. The National Institute for Health Research (NIHR) has confirmed it is supportive of the application of this guidance.&amp;quot;

Finally, the PI, together with colleagues within the Network have contributed to a publications from Springer Nature entitled &amp;quot; Publishing descriptions of non-public clinical datasets: guidance for researchers, repositories, editors and funding organizations&amp;quot;
Following a consultation, their comments have been used to revise these guidelines.</gtr:impact><gtr:outcomeId>E7rr4jsMXP2-2</gtr:outcomeId><gtr:partnerContribution>Network funding provided for project commencement</gtr:partnerContribution><gtr:piContribution>Network funded proposal- This proposal addresses a main priority area for the HTMR Network, that of using
existing evidence in the prioritisation, design and planning, conduct, and interpretation
of trials, all of which can be helped by improving access to clinical trial data.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ICTMC2015 - Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D1783EE2-A429-4A34-9362-E6F9A4B68523</gtr:id><gtr:impact>The HTMR Network organised the 3rd International Clinical Trials Methodology Conference (ICTMC2015) at Glasgow in November 2015.
Over 600 delegates attended. The conference included parallel presentations of new methods, plenary talks and keynote discussions.</gtr:impact><gtr:outcomeId>56b09dd1d44a16.87162170</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://ictmc.uk/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trial Conduct Working Group- webinar on-site monitoring</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8E452BD5-DD92-4888-853E-F365FCA0B5C8</gtr:id><gtr:impact>Trial Conduct WG organised a webinar on Developing evidence-based approaches to use of on-site monitoring in October 2014. This stimulated discussion and consideration of a specific methodology research topic

discussion and slides available following meeting</gtr:impact><gtr:outcomeId>545a16193a0e03.30906933</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.methodologyhubs.mrc.ac.uk/pdf/evidence-based%20approaches.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>2014 4th student symposia HTMR</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2CD93522-48DA-4812-9ACE-CB20C8ECCF6A</gtr:id><gtr:impact>Student meeting- organised by London Hub to encourage engagement within the student cohort

Feedback from the workshop was positive, with many students highlighting this was a perfect eent to engage with their methodology peers</gtr:impact><gtr:outcomeId>545a3fa015ca59.15743108</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Population Health Sciences Research Network (PHSRN)</gtr:department><gtr:description>Cross-Unit Appointment: Using causal analyses to add value to large RCTs</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>35BCFB6A-2038-4379-9D4D-ED71C85ECD26</gtr:id><gtr:outcomeId>MYiZBaAN5DT</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Hub for Trials Methodology Research (HTMR) - extension</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BF882DDE-07EB-49B0-BF97-46C00CE77FBC</gtr:id><gtr:outcomeId>5464a2ad0d46d7.96260885</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Population Health Sciences Research Network (PHSRN)</gtr:department><gtr:description>Cross-Unit Appointment: Strategies to reduce attrition in RCTS</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7F2A77E9-B8BD-4A5C-9056-13647BD63086</gtr:id><gtr:outcomeId>cvj1GFXTAav0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Fellowship: Analysis of recurrent events in clinical trials</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>0BEA645E-EF7E-483F-8DDE-C76091B4547A</gtr:id><gtr:outcomeId>545ba3ff911338.68063050</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>136000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC HTMR Network award- Adaptive Design Outreach officer</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>C1FC0F74-F0C9-454A-B786-316111BA2A7B</gtr:id><gtr:outcomeId>56d6b48c74fe60.62718332</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>136000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Hubs for Trial Methodology Research</gtr:department><gtr:description>MRC HTMR Network award</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>HTMR B1</gtr:fundingRef><gtr:id>E4A72E21-C5BE-40A4-8C94-EF5491D4CB0F</gtr:id><gtr:outcomeId>545a12d3cb3ca0.60157606</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23260</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Network of Hubs for Trials Methodology Research (HTMR)</gtr:department><gtr:description>Workshops, small projects, other Hub events:The use of individual participant data (IPD) in systematic reviews</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2B2F488B-88D8-4FE5-B5CD-5EEE38AA6610</gtr:id><gtr:outcomeId>hA5LrgzBkxb</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205540</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CR UK Population Science Committee, Project Grant (TEMPER study)</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C1495/A13305</gtr:fundingRef><gtr:id>6E6F70B7-8370-450D-8EB7-3E013030D648</gtr:id><gtr:outcomeId>ZCZr7yNCLvN0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing understanding of statisics for clinical trials: IDMCs presentation at the EORTC staistics for non statistician course</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>2AE5BACF-9D62-407B-8481-FB4352F04E72</gtr:id><gtr:outcomeId>545a027353a526.57851673</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing clinical guidelines: NICE consultation for new guidelines on sleeping of newborn infants</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6FEB704B-A812-4706-A668-1ACE91981674</gtr:id><gtr:outcomeId>545b9a25b6d498.90149290</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing statistical practice: Multiple Imputation and its Application</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A138D2C7-EAC8-4D09-9E52-D768FC619439</gtr:id><gtr:outcomeId>545b997050a7b4.41639546</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Workshop on mult-arm mult-stage (MAMS) trials</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71BCBC61-06F3-4843-91D5-B52C5F9495BA</gtr:id><gtr:outcomeId>XKvpJXa5Qn7</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>INVOLVE guidance for researchers on patient and public involvement in clinical trials</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0868EA9B-EC80-44B3-A7BC-B5E994D40A13</gtr:id><gtr:outcomeId>HEM1EBWgG5N</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial analysis: Comparison of dynamic treatment regimes/monitoring strategies (DART)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4922EFE0-7475-4705-9ED7-CFD362C92090</gtr:id><gtr:outcomeId>MXMZ8297jdY</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20347483</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial analysis: Use of Restricted Mean Survival Time method in CTU-led clinical trials (ICON7)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>77DFA905-4C5C-4BEC-AC18-0D6207509AB3</gtr:id><gtr:outcomeId>rPfLu5gyveQ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Methodological Expectations of Cochrane Intervention Reviews: Searching for Studies</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>89DACC3A-0C98-4A39-A866-6C899832142B</gtr:id><gtr:outcomeId>LjFP3EcMF7b</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing analysis of survey and trial data: Multiple imputation and inverse probability weighting</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EBFE4B28-F06D-460A-B49C-128D64B07179</gtr:id><gtr:outcomeId>jEQCBdJXA1B</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial design: Use of TAMS design in CTU-led clinical trials</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>12D3B420-5265-47EC-AD81-F873C33994E6</gtr:id><gtr:outcomeId>ea6mbF28L3k</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial design: Use of biomarker designs in CTU-led cancer clinical trials (FOCUS4)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EA894CBF-8902-427F-9F6A-842300D56057</gtr:id><gtr:outcomeId>r8zRZUKYe55</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>INVOLVE guidance for researchers on patient and public involvement in systematic reviews</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>905F83BF-F82B-41F8-9178-8B7A9EEE7075</gtr:id><gtr:outcomeId>rdLwCeCC16y</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing understanding of clinical trial designs: MAMs trials presentation at network HTMR PhD students meeting</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1224F94D-C914-4ABB-8464-AFCBB9509A0F</gtr:id><gtr:outcomeId>545a0588173b70.51610364</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing understanding of statistics for clinical trials: Presentation at the Yorkshire Mens Health Forum</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>2A1F5F0F-EAED-4B8E-B11D-A8CEE7F47F28</gtr:id><gtr:outcomeId>545a03b92f7ef8.81617655</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing analysis of data in meta-analysis: Analysis of treatment by patient covariate interactions in meta-analysis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>848C4D11-C2A3-44BC-ADBB-04504D87170A</gtr:id><gtr:impact>Use of this method has become standard in MRCCTU-led meta-analysis of IPD and has also been applied in MRC CTU meta-anlayses of aggregate data. The method has also been used to analyse subgroup interactions in IPD meta-analyses at the Institute Gustav Roussy (France). It has also been presented at national and international conferences</gtr:impact><gtr:outcomeId>qenQfy67CWq</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing practice relating to dropout from longitudinal clinical trials</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>08FCBBB0-B686-4112-8558-C5E54D257FD4</gtr:id><gtr:impact>Research on reference based sensitivity analyses for longiudianl clincal trials with dropout is continuing to influence practice. A Drug information workking group discussion is hosted on the website of a senior member of CTU statistical methodology staff (James Carpenter) and the methodology has been used in a number of regulatory submissions from companies</gtr:impact><gtr:outcomeId>545b98b652f5c4.61770173</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.missingdata.org.uk</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing understanding of statistics for clinical trials: IDMCs presentation, FLIMs 2014 Course</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>B4BA48E5-ED4B-4850-B1B0-46453C9D1747</gtr:id><gtr:outcomeId>545a02e5de3255.98468866</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing understanding of statistics for clinical trials: Software for sample size calculations. A presentation at the FLIMs 2014 course</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>2B88BB9F-E540-4117-94E1-BC918F73F1DC</gtr:id><gtr:outcomeId>545a0352b77cf2.44637632</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial design: Use of MAMS design in CTU-led and other clinical trials</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>50FE9FD4-C896-40B3-89A0-87DC73F6384B</gtr:id><gtr:outcomeId>gJyLdf54mwW</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing Data sharing: Data Transparency and data sharing: an academic CTU perspective. Presentation at PSI annual conference</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>759ED196-B92C-4F67-8C35-EEEC979F0AB4</gtr:id><gtr:outcomeId>545a01e70454c8.81057810</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Statistical design of phase III trials: A presesntation at the All Ireland Cooperative Oncology Group Conference</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>00086328-5222-4A69-86F3-98A246F6AEAD</gtr:id><gtr:outcomeId>545a007f8c9f23.05517932</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing statistical anlaysis of clinical trials: restricted mean survival times to analyse trials with non-proportional hazards (Add Aspirin)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>5D6E0766-C9C3-47EC-A376-0BB8E4E04CE1</gtr:id><gtr:outcomeId>545bb012c70ad2.86698989</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Multi-arm multi-stage randomised controlled trials: an adaptive design: A statistical seminar at the Royal Free Hospital</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>1399A5BE-2D4E-4876-B6B3-10D70C80F2C9</gtr:id><gtr:outcomeId>5459ff668b83c7.10271528</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Joint project risk-adapted guidance</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3556D938-5990-4002-A687-1DF7E6622009</gtr:id><gtr:outcomeId>eFQNUgqzePd</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial design: Use of ART in CTU-led and other clinical trials</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1134D207-3565-43CD-8047-168FAC7ED7F6</gtr:id><gtr:outcomeId>tjEheFN5zmZ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial analysis: Use of flexible parametric survival analysis in CTU-led cancer clinical trials (ASTEC)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>63ABDACC-382B-46FD-976F-BD165700F1E0</gtr:id><gtr:outcomeId>i2BZU73xUYy</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.amazon.co.uk/Flexible-Parametric-Survival-Analysis-Using/dp/1597180793/ref=sr_1_1?s=books&amp;ie=UTF8&amp;qid=1349693216&amp;sr=1-1</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in a new FDA guidance document</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>13D7A403-0ED8-4EE9-86E2-DD2DA8908029</gtr:id><gtr:outcomeId>545784aa4e3458.16199305</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm269919.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing trial analysis: Estimating the effect of time-varying treatment (ARROW trial)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4A2943C0-213C-4C64-8B53-6FB6EBCE3C84</gtr:id><gtr:outcomeId>TLYCsVwS9Bh</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://europepmc.org/abstract/MED/20347483</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IDMC guidance for research ethics committees</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>17C1FA0C-1C76-44C2-8AD1-C5EF66582E37</gtr:id><gtr:outcomeId>Yh2PYbeseVu</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Workshop and guidance on IPD meta-analysis</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C1E9D36D-1DD5-4C39-8CD4-3F7CC01F13D1</gtr:id><gtr:outcomeId>mrb48DZyX1d</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Influencing analysis of CTU-led and other cohort studies: Modelling association between patient characteristics and change over time in a disease measurement</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>86D5A7D7-7309-44AF-8247-F659BBE8E047</gtr:id><gtr:outcomeId>qoV14B4zP4e</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The Stata package &amp;quot;ipdmetan&amp;quot; comprises a set of routines for conducting two-stage individual participant data (IPD) meta-analysis, and associated functionality. The main routine &amp;quot;ipdmetan&amp;quot; fits a specified regression model to the data from each study in turn, extracts the specified effect size and standard error, and generates pooled effects, heterogeneity statistics etc. as appropriate. Various random-effects models are available. The routine also provides the novel facility of including aggregate data from an external dataset; for instance if IPD were not available for some studies.
The routine &amp;quot;forestplot&amp;quot; is a re-written and extended version of the graphics routine within the existing Stata command &amp;quot;metan&amp;quot;. As well as being called by &amp;quot;ipdmetan&amp;quot;, it is also designed to be run independently on saved datasets, allowing more complex forestplots to be created.
The package also includes the routines &amp;quot;admetan&amp;quot;, which performs inverse-variance aggregate-data meta-analysis as a direct alternative to the existing Stata command &amp;quot;metan&amp;quot;; and &amp;quot;petometan&amp;quot;, which performs meta-analysis on binary or time-to-event data using the Peto (log-rank) method.
Finally, the routine &amp;quot;ipdover&amp;quot; extracts effect sizes and standard errors within each level of each member of a list of categorical variables, to create a forestplot summarising subgroup results for a single randomised trial.</gtr:description><gtr:id>BD4E1149-C15F-40C9-B526-8F39326BF3A2</gtr:id><gtr:impact>The package is available from the SSC archive and can be found and installed from within Stata by typing &amp;quot;ssc describe ipdmetan&amp;quot; and &amp;quot;ssc install ipdmetan&amp;quot; respectively. Since it's release within the archive, the software has been downloaded 70 times per month on average.
A Stata Journal article describing the functionality of the package is in press</gtr:impact><gtr:outcomeId>545bbc7790cee2.69657133</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>STATA CODE FOR PERFORMING TWO-STAGE INDIVIDUAL PARTICIPANT DATA META-ANALYSIS</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:url>http://econpapers.repec.org/software/bocbocode/s457785.htm</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>STATA software</gtr:description><gtr:id>6DC4F794-C300-4005-AED7-7E72673FF432</gtr:id><gtr:impact>Facilitates flexible parametric survival modelling using STATA.
Software is available to download from the publicly available Statistical Software Compnents (SSC) arvhive from where it has been downloaded in the region of 100 times per month since late 2012</gtr:impact><gtr:outcomeId>hJ8iAjLoEZM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Flexible parametric survival modelling: STATA stpm software and updates</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>STATA code</gtr:description><gtr:id>DABBD014-2737-4490-B0E5-0A4195E6DC4F</gtr:id><gtr:impact>Has allowed this improved methodolgy to analyse patient subgroup interactions to be implemented in IPD meta-analysis.</gtr:impact><gtr:outcomeId>i4R8KFrfjMq</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Analysis of patient subgroup interactions in IPDMA: STATA software</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Stata software to calculate required sample size for trials with time-to-event outcomes</gtr:description><gtr:id>F434CBB0-F720-460F-8AD9-9E2FF6685460</gtr:id><gtr:impact>This software is freely available and is now the standard tool for sample size calculation both at the MRC Clinical Trials Unit and at other units. Currently, further developments include extedning the software for clinical trials with binary outcomes.</gtr:impact><gtr:outcomeId>MFjgafsDsS3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ART sample size software</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Updates to software in Stata to perform multiple imputation, a technique for dealing with missing data. Developed in collaboration with others.</gtr:description><gtr:id>179C05BA-3734-4C8B-B407-1CDE433B1443</gtr:id><gtr:impact>Used internationally by stata users when analysing medical research data. In 2011 became standard Stata command.
ICE and MIM programs are available through the publicly accessible Statistical Software Components (SSC) archive from where the software has been downloaded in the region of 200 times per month since September 2012</gtr:impact><gtr:outcomeId>tj8eAuSe9Zi</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Stata multiple imputation updates</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>STATA software. Currently being further developed for different outcomes types (i.e. trials with binary outcomes) and also for use in other statistical packages (e.g. R)</gtr:description><gtr:id>CF473548-7B9D-4E1B-9238-EB441F65AFF3</gtr:id><gtr:impact>Aids in the design of MAMS trials. Access to this sotfware facilitates the design and implementation of such trial designs by others.</gtr:impact><gtr:outcomeId>CjcLGCcRXUw</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MAMS trial design: STATA nstage software</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E0C0E117-7396-40E8-B94E-B86E1279487A</gtr:id><gtr:title>Estimating within-study covariances in multivariate meta-analysis with multiple outcomes.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74c7527dc2bbf15fadf582ed815befa6"><gtr:id>74c7527dc2bbf15fadf582ed815befa6</gtr:id><gtr:otherNames>Wei Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23208849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D41C7FC-9D2C-431E-B2BB-F99F784D2725</gtr:id><gtr:title>Handbook of Missing Data</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2900a3708f2995491fa17f0ac45080b1"><gtr:id>2900a3708f2995491fa17f0ac45080b1</gtr:id><gtr:otherNames>Goldstein, H. and Carpenter, J. R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a2ff66ab693.91776164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DFEB8EA-57EC-4874-AE58-B6BC61A69F95</gtr:id><gtr:title>The Complementary Exponentiated Exponential Geometric Lifetime Distribution</gtr:title><gtr:parentPublicationTitle>Journal of Probability and Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7637286446402d428ff281b8d336c5b"><gtr:id>e7637286446402d428ff281b8d336c5b</gtr:id><gtr:otherNames>Louzada F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>TtEFSJg7R7v</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6676089-E123-48DA-BC60-6B838EC30266</gtr:id><gtr:title>Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c34e94bd25d0c4d84818d65e5b6d975"><gtr:id>2c34e94bd25d0c4d84818d65e5b6d975</gtr:id><gtr:otherNames>Bartlett JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>545a2071d66215.48864804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF15F13A-5665-4941-B4C8-D85A24F5B367</gtr:id><gtr:title>Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d16a0e2cac032025257ed2f44c93f19d"><gtr:id>d16a0e2cac032025257ed2f44c93f19d</gtr:id><gtr:otherNames>Crook AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn><gtr:outcomeId>56d7462e71f3e3.97483607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A75F3BAA-71A2-447F-BD19-1207130C098A</gtr:id><gtr:title>A simulation study of predictive ability measures in a survival model II: explained randomness and predictive accuracy.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d23ceb7e3c56afc2a019d40d709e8c11"><gtr:id>d23ceb7e3c56afc2a019d40d709e8c11</gtr:id><gtr:otherNames>Choodari-Oskooei B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_22764064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40655AE5-274B-415C-822F-FC5EDF50BB21</gtr:id><gtr:title>Bootstrap assessment of the stability of multivariable models</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>jhh1Buy8ukP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03643B98-CF46-4334-A053-0280657ECD65</gtr:id><gtr:title>Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b406fab6ba11014e7aaae158195c4493"><gtr:id>b406fab6ba11014e7aaae158195c4493</gtr:id><gtr:otherNames>Wright CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>pm_13787_27_22937795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9886730-6754-45EE-B1BD-D4E0CBCBCB66</gtr:id><gtr:title>Comments on 'A modest proposal for dropping poor arms in clinical trials' by Proschan and Dodd.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>587de329109329.50605774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>446A5B9C-91C5-47E4-9C55-88159E4C68D3</gtr:id><gtr:title>Two techniques for investigating interactions between treatment and continuous covariates in clinical trials</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>Z757f2XE8uR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D91FCA71-3D54-49CB-B486-62C373261B2E</gtr:id><gtr:title>Correcting for optimistic prediction in small data sets.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a336bb3c8de14a5560db098945d61c3"><gtr:id>5a336bb3c8de14a5560db098945d61c3</gtr:id><gtr:otherNames>Smith GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>5457911834d0f2.01000749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F03AEE5C-E07B-4C84-B89F-C54A7737D6BE</gtr:id><gtr:title>Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9f8b490c0ae563537366df960a54b14"><gtr:id>a9f8b490c0ae563537366df960a54b14</gtr:id><gtr:otherNames>Neaton JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>R3bHa9rQ6he</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71B09EB5-003B-40BD-81D0-2DF93F14A531</gtr:id><gtr:title>Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.</gtr:title><gtr:parentPublicationTitle>Epidemiology (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54018cfb81d32f3e685bdfda584eb66f"><gtr:id>54018cfb81d32f3e685bdfda584eb66f</gtr:id><gtr:otherNames>Ewings FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1044-3983</gtr:issn><gtr:outcomeId>545793004dab73.32711197</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C1562D4-75B9-47B2-B661-592A53E744BB</gtr:id><gtr:title>Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2e58423bc86283bf8ce7ed9f5afcdef"><gtr:id>d2e58423bc86283bf8ce7ed9f5afcdef</gtr:id><gtr:otherNames>Manola J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>W5YwmFMMUG1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>149BBBD2-F1E7-435D-9C53-955D3DEE943B</gtr:id><gtr:title>An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ea73e5c0a9951b8511cd9c8aec3c510"><gtr:id>2ea73e5c0a9951b8511cd9c8aec3c510</gtr:id><gtr:otherNames>Phillips PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13787_27_23667677</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD2A6546-39FF-4639-8422-E042DEC4DCA0</gtr:id><gtr:title>Quantifying the uptake of user-written commands over time</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83dd8b15142e903637fcb1c70faff1cb"><gtr:id>83dd8b15142e903637fcb1c70faff1cb</gtr:id><gtr:otherNames>Choodari-Oskooei Babak</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>587de328927cd3.21709919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8CC9D17-C6B2-4EAF-BF04-66AD54DA9304</gtr:id><gtr:title>Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>5457b4555dee45.40824140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13C0BFB2-0DE7-4A48-9189-ADE559F202F5</gtr:id><gtr:title>Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a409def97754c3f9b5001e11f39b5b7d"><gtr:id>a409def97754c3f9b5001e11f39b5b7d</gtr:id><gtr:otherNames>Babiker AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>pm_13787_27_22547421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>643E07F8-228A-4ED2-B89F-0A4EA0D1E643</gtr:id><gtr:title>Choosing sensitivity analyses for randomised trials: principles.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b1d9399bd3eb60d72d90806cff36fc5"><gtr:id>0b1d9399bd3eb60d72d90806cff36fc5</gtr:id><gtr:otherNames>Morris TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>54579300c67021.89357479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EA2D54A-B8DA-443F-97D9-DA0B29A6632B</gtr:id><gtr:title>Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>587de3279cc006.68735342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D329B693-FF99-46C2-935C-01BBF7FFCDA2</gtr:id><gtr:title>A Quantitative Process for Enhancing End of Phase 2 Decisions.</gtr:title><gtr:parentPublicationTitle>Statistics in biopharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b44fc9d9e00883f5049d625315c81b8"><gtr:id>7b44fc9d9e00883f5049d625315c81b8</gtr:id><gtr:otherNames>Sabin T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1946-6315</gtr:issn><gtr:outcomeId>5457921835a180.93891145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>366701FD-F358-41D0-BAFC-976461048377</gtr:id><gtr:title>Response to comments by Seaman et al. on &amp;quot;Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation,&amp;quot; Journal of Biopharmaceutical Statistics 23:1352-1371.</gtr:title><gtr:parentPublicationTitle>Journal of biopharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58e09bc75753601cbcf46d0992f62267"><gtr:id>58e09bc75753601cbcf46d0992f62267</gtr:id><gtr:otherNames>Carpenter JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1054-3406</gtr:issn><gtr:outcomeId>545763e7db7183.05352044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0A0AD91-F3A8-4B27-BBB4-05D6D611C869</gtr:id><gtr:title>Strategies to improve retention in randomised trials.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ebf169d9f9376e24723f13c155e417b"><gtr:id>9ebf169d9f9376e24723f13c155e417b</gtr:id><gtr:otherNames>Brueton VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>5457b4558b3ef8.09632246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52D2E3AF-AB7D-49E6-826F-7C3014E38A71</gtr:id><gtr:title>Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>a9wGhTN9Zmo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4E8B95D-657C-41F9-AD03-93E35B0C8DF9</gtr:id><gtr:title>Projection of power and events in clinical trials with a time-to-event outcome</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>ESuZDWhq165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59E8E7EF-9636-4A8A-B863-D1B3090C4D60</gtr:id><gtr:title>An efficient record linkage scheme using graphical analysis for identifier error detection.</gtr:title><gtr:parentPublicationTitle>BMC medical informatics and decision making</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11de4deaa8aa9335ae592c02c0645989"><gtr:id>11de4deaa8aa9335ae592c02c0645989</gtr:id><gtr:otherNames>Finney JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1472-6947</gtr:issn><gtr:outcomeId>BTpEtDdCiyG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA6B2D81-36EE-493B-96C9-02125C8FDEBF</gtr:id><gtr:title>Trial steering committees for randomised controlled trials: updating and redeveloping guidance and terms of reference informed by current practice and experience</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4453a28531c12fe1fd4e1b79a8e5591f"><gtr:id>4453a28531c12fe1fd4e1b79a8e5591f</gtr:id><gtr:otherNames>Conroy E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5459fb1edc8b11.68880979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F464770-AD94-4A47-9296-9A3203118F1B</gtr:id><gtr:title>Further development of flexible parametric models for survival analysis</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d90016b1514e4077b019bbe3ae3897e"><gtr:id>6d90016b1514e4077b019bbe3ae3897e</gtr:id><gtr:otherNames>Lambert Paul C.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>hV1zSVCssFw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51F69800-ECEE-4459-9A75-B86705F74E0E</gtr:id><gtr:title>Assessing potential sources of clustering in individually randomised trials.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_13787_27_23590245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57EBA541-3500-4F7D-8F38-C30B1FF73791</gtr:id><gtr:title>Modelling continuous exposures with a 'spike' at zero: a new procedure based on fractional polynomials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>WMs4KftPC6j</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5788F80-0FA0-4D05-97E6-F4DDE8EEB0B6</gtr:id><gtr:title>Bayesian multivariate meta-analysis with multiple outcomes.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74c7527dc2bbf15fadf582ed815befa6"><gtr:id>74c7527dc2bbf15fadf582ed815befa6</gtr:id><gtr:otherNames>Wei Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23386217</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28F07DFF-6B78-4B5F-A399-098710590AA5</gtr:id><gtr:title>Major Greenwood's early career and the first departments of medical statistics.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8e4acfc564c4a9e7aaa421228e10cc6"><gtr:id>a8e4acfc564c4a9e7aaa421228e10cc6</gtr:id><gtr:otherNames>Farewell V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>56cc529f4d48b4.20339135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEF45593-7684-418F-8068-647396253D5F</gtr:id><gtr:title>Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13787_27_22978443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D6291D2-5713-4055-9FBB-6C3911DB4C42</gtr:id><gtr:title>Comparison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8082ef5a08decc6a91548b81bb18a17"><gtr:id>b8082ef5a08decc6a91548b81bb18a17</gtr:id><gtr:otherNames>Marshall A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>CjHvNgae2Tm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C17AA52-AE45-46EA-8C5D-4218553AFF1D</gtr:id><gtr:title>The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>54579217d375a2.34911490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63BFDE41-9A1D-477D-BF2A-F82DEEA37E71</gtr:id><gtr:title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1aaa9a206a1a008b44f5aaa374ba688e"><gtr:id>1aaa9a206a1a008b44f5aaa374ba688e</gtr:id><gtr:otherNames>Eisenhauer EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>dcWA8CPE38n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDED3A52-0714-47EB-8E32-52E1437E4BE9</gtr:id><gtr:title>Measuring the impact of methodological research: a framework and methods to identify evidence of impact.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ebf169d9f9376e24723f13c155e417b"><gtr:id>9ebf169d9f9376e24723f13c155e417b</gtr:id><gtr:otherNames>Brueton VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56c702636b0f07.53738113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCCB90AC-8473-47E7-9608-D229E23E23E4</gtr:id><gtr:title>cmpute: A tool to generate or replace a variable.</gtr:title><gtr:parentPublicationTitle>The Stata Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e52c8992cb871930109e46422185e21"><gtr:id>2e52c8992cb871930109e46422185e21</gtr:id><gtr:otherNames>Royston P.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5457b2aeda6387.95004617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DD12FEE-8F2C-47F6-9C63-0FAC5F5291D2</gtr:id><gtr:title>Visualizing and assessing discrimination in the logistic regression model.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>U34DpU6Fzc8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20C77609-8D08-4EA5-8594-9D0FD63C1F85</gtr:id><gtr:title>Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7b9f88de7989208d17352d3514ca24"><gtr:id>1e7b9f88de7989208d17352d3514ca24</gtr:id><gtr:otherNames>Bowden J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>Vaj7meAYCns</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37424B89-3EB1-4F50-8FAC-0B607614C7BD</gtr:id><gtr:title>Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8082ef5a08decc6a91548b81bb18a17"><gtr:id>b8082ef5a08decc6a91548b81bb18a17</gtr:id><gtr:otherNames>Marshall A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>KyVHLxcmvEK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D1DC075-22A2-4417-9A78-68935A4E4950</gtr:id><gtr:title>The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>XjgeKYA4ibs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4C8FB1B-09CC-41B1-AE96-194ABF366659</gtr:id><gtr:title>Emotion Detection in Suicide Notes using Maximum Entropy Classification.</gtr:title><gtr:parentPublicationTitle>Biomedical informatics insights</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae8d808c2fc2ab4b5039e82865aa07f4"><gtr:id>ae8d808c2fc2ab4b5039e82865aa07f4</gtr:id><gtr:otherNames>Wicentowski R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1178-2226</gtr:issn><gtr:outcomeId>pm_13787_27_22879760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6BA3CDB-6941-4FA7-9C10-650D64DACECD</gtr:id><gtr:title>Adjusting for multiple prognostic factors in the analysis of randomised trials.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_13787_27_23898993</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED6D9F68-B884-4C72-A982-AF5B17E53DE3</gtr:id><gtr:title>Imputing missing covariate values for the Cox model.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bd522716636d6c40c2c616ae992e297"><gtr:id>9bd522716636d6c40c2c616ae992e297</gtr:id><gtr:otherNames>White IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>sJJckhA6diE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>431D4164-3111-42EC-885C-B8337EE67593</gtr:id><gtr:title>SPIRIT 2013 statement: defining standard protocol items for clinical trials.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffd2b6f761735abf8866e1b9cdefd50a"><gtr:id>ffd2b6f761735abf8866e1b9cdefd50a</gtr:id><gtr:otherNames>Chan AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>pm_13787_27_23295957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F14BF79E-D3BE-4782-BA6F-88E0136D952E</gtr:id><gtr:title>Applying for ethical approval for research in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e61d9d70d39d7942eb7179fd7d724d3"><gtr:id>8e61d9d70d39d7942eb7179fd7d724d3</gtr:id><gtr:otherNames>Smajdor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>q9uETJxjy4J</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3A2F1F6-FE02-4BAC-81AA-153A94E3B148</gtr:id><gtr:title>Flexible parametric survival analysis using Stata: beyond the Cox model</gtr:title><gtr:parentPublicationTitle>Stata Press</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>978-1-59718-079-5</gtr:isbn><gtr:outcomeId>GdqGGh35zij</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFCAFB23-1F60-45C1-8B89-AA85BFB90575</gtr:id><gtr:title>Methods for observed-cluster inference when cluster size is informative: a review and clarifications.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddaa0a8b3f093f80e3577c6ca6033bfb"><gtr:id>ddaa0a8b3f093f80e3577c6ca6033bfb</gtr:id><gtr:otherNames>Seaman SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>5457930076a902.23637143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>404F2760-F6D6-4C91-922E-94D29CF90943</gtr:id><gtr:title>marginsplot: plotting the marginal effects of continuous predictors</gtr:title><gtr:parentPublicationTitle>Stata Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>LSAe377ggPG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8FD6585-6EBC-42A3-9940-8BD370D5ED66</gtr:id><gtr:title>The extension of total gain (TG) statistic in survival models: properties and applications.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d23ceb7e3c56afc2a019d40d709e8c11"><gtr:id>d23ceb7e3c56afc2a019d40d709e8c11</gtr:id><gtr:otherNames>Choodari-Oskooei B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>587de32945e340.85792752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A7562AD-67E5-4556-A78E-5E3FB90CDEB2</gtr:id><gtr:title>Comparison between splines and fractional polynomials for multivariable model building with continuous covariates: a simulation study with continuous response.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dd66b61ddbb80589d67b45397bfde09"><gtr:id>2dd66b61ddbb80589d67b45397bfde09</gtr:id><gtr:otherNames>Binder H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23034770</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>203DB57E-E0CA-4C97-99DD-F4B88125A400</gtr:id><gtr:title>Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>DePG7he6Qkn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE156A9A-87B4-4BD2-9AA4-850EF4FCFBC0</gtr:id><gtr:title>Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>kPHyA9Wsd8n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91854F18-BE37-40B4-B878-C93A6BB1D89B</gtr:id><gtr:title>Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>TbAFY8PDXBR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D17B0633-FD16-409C-9F22-40A95FEC2B3B</gtr:id><gtr:title>Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf39766f2c58c53463ac157701e94718"><gtr:id>cf39766f2c58c53463ac157701e94718</gtr:id><gtr:otherNames>Burnell M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>ctqqp8XTMqw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA925C1B-1D78-40D6-99BC-544A46869566</gtr:id><gtr:title>Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d06f83aa69c60e52c87568112f6cce96"><gtr:id>d06f83aa69c60e52c87568112f6cce96</gtr:id><gtr:otherNames>Marston L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545a21148bf4c5.96126196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BD62059-0432-4E43-BC1E-1159C4355EA9</gtr:id><gtr:title>A re-randomisation design for clinical trials.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>56d6dcbe544ce1.79938491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0686294D-1CE0-4416-B59F-FA3C69D46967</gtr:id><gtr:title>Meta-analysis of time-to-event data: a comparison of two-stage methods.</gtr:title><gtr:parentPublicationTitle>Research synthesis methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23e06e71eae2899b30d5b3a677f49636"><gtr:id>23e06e71eae2899b30d5b3a677f49636</gtr:id><gtr:otherNames>Simmonds MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1759-2879</gtr:issn><gtr:outcomeId>hrMpU1vuMy8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>624E20B7-C9C4-43E1-A534-46970BB24A93</gtr:id><gtr:title>Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1437662d2ddeda92da753b4b2a41f3c"><gtr:id>d1437662d2ddeda92da753b4b2a41f3c</gtr:id><gtr:otherNames>Farmer RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>58b98c81d7e573.29152218</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B603EB4-7EB7-4E71-B3FC-62568CA4A734</gtr:id><gtr:title>Risk prediction models: II. External validation, model updating, and impact assessment.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea46aa157f53303836291b13e8e0a302"><gtr:id>ea46aa157f53303836291b13e8e0a302</gtr:id><gtr:otherNames>Moons KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>pm_13787_27_22397946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>601DB507-67C5-4F60-9514-72685ACFF472</gtr:id><gtr:title>Recommendations for the assessment of progression in randomised cancer treatment trials.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36f98906157f124dce6a14080f77afa6"><gtr:id>36f98906157f124dce6a14080f77afa6</gtr:id><gtr:otherNames>Dancey JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>VPZf49BJ8U3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6B66142-F81E-4A07-AF23-F135F88C39B0</gtr:id><gtr:title>The FOCUS4 design for biomarker stratified trials.</gtr:title><gtr:parentPublicationTitle>Chinese clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723c80601d0630665bb715ff60df02b8"><gtr:id>723c80601d0630665bb715ff60df02b8</gtr:id><gtr:otherNames>Kaplan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2304-3865</gtr:issn><gtr:outcomeId>56dc4a75d3a312.68136513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67B7FEB4-5B2C-4871-ACE5-FCBDCE304878</gtr:id><gtr:title>Reporting methods in studies developing prognostic models in cancer: a review.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/576b14cff8e7d733fb1225b563732a59"><gtr:id>576b14cff8e7d733fb1225b563732a59</gtr:id><gtr:otherNames>Mallett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>Zk4ioP6mqmc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2985AC00-D766-42DA-B84E-49602F524299</gtr:id><gtr:title>Handbook of Missing Data</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c49bd7ed334921280b4ab6dde4a0a5b4"><gtr:id>c49bd7ed334921280b4ab6dde4a0a5b4</gtr:id><gtr:otherNames>Carpenter, J. R. and Kenward, M. G.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a30bf5fa472.26447159</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F444622-BAFB-43B9-8C74-2D6F54DFF7DE</gtr:id><gtr:title>Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_13787_27_23610376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97B49B18-6434-4BC7-9938-CD1C806EBD86</gtr:id><gtr:title>Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23580422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E1189F0-9EE5-4343-B904-FA3C7066860F</gtr:id><gtr:title>A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42512b7820226856cb47284e29a7903a"><gtr:id>42512b7820226856cb47284e29a7903a</gtr:id><gtr:otherNames>Barthel Friederike M-S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>kekyaHpCPdH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53ED88BD-8EE5-437A-AA7C-71DF5CCF035F</gtr:id><gtr:title>Evaluating many treatments and biomarkers in oncology: a new design.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/723c80601d0630665bb715ff60df02b8"><gtr:id>723c80601d0630665bb715ff60df02b8</gtr:id><gtr:otherNames>Kaplan R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>bRKeoQv3w9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A9753B7-9968-4B51-857D-3219C8A24AF4</gtr:id><gtr:title>Analysis of multicentre trials with continuous outcomes: when and how should we account for centre effects?</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23112128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90BD1D74-AB9E-4F8B-8B6D-3921C2982F9C</gtr:id><gtr:title>The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b845507a87257cb3fbd03f2c3ea6cc40"><gtr:id>b845507a87257cb3fbd03f2c3ea6cc40</gtr:id><gtr:otherNames>Bakobaki JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>hQqaAVAAxGn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BC57508-F129-4FEA-A148-CED974F1A37E</gtr:id><gtr:title>Cochrane Database of Systematic Reviews - Protocols</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be104b9f859b1182f6dcc12403f7d6ec"><gtr:id>be104b9f859b1182f6dcc12403f7d6ec</gtr:id><gtr:otherNames>Brueton V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1996-01-01</gtr:date><gtr:outcomeId>WdbBciJwMwB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AE3C693-EB5D-44DF-8623-D8737603D958</gtr:id><gtr:title>The consequences of randomizing schools rather than children.</gtr:title><gtr:parentPublicationTitle>The Journal of school health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-4391</gtr:issn><gtr:outcomeId>54579218098755.55748716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD6EB12-5238-4543-BB5E-6B436D6ED20B</gtr:id><gtr:title>Statistical analysis of an endemic disease from a capture-recapture experiment</gtr:title><gtr:parentPublicationTitle>Journal of Applied Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74c7527dc2bbf15fadf582ed815befa6"><gtr:id>74c7527dc2bbf15fadf582ed815befa6</gtr:id><gtr:otherNames>Wei Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>oX99WUXv71k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B6D2C4-17DD-4681-B64E-D4287767D953</gtr:id><gtr:title>Evaluation of patient involvement in a systematic review and meta-analysis of individual patient data in cervical cancer treatment.</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn><gtr:outcomeId>pm_13787_27_22587912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3A9B0DB-F82D-4066-BAF4-BAF5676439EE</gtr:id><gtr:title>A comparison of methods to adjust for continuous covariates in the analysis of randomised trials.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>585d50c4305660.85864957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBEC7C78-5D6A-4B32-A68B-F6BF3CCCFAB1</gtr:id><gtr:title>Prognosis and prognostic research: application and impact of prognostic models in clinical practice.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea46aa157f53303836291b13e8e0a302"><gtr:id>ea46aa157f53303836291b13e8e0a302</gtr:id><gtr:otherNames>Moons KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>p8dxvxLoyGP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>981369AE-98AC-4B66-9EDB-2B1E9C623B36</gtr:id><gtr:title>Predictive performance of surgical severity scores for risk of infant mortality of newborns with congenital heart defects (CHD): a population-based survival analysis study (the EPICARD cohort study)</gtr:title><gtr:parentPublicationTitle>BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a10ed2e0768ed1a7a562858734fd88f0"><gtr:id>a10ed2e0768ed1a7a562858734fd88f0</gtr:id><gtr:otherNames>Rahshenas M.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1542-0752</gtr:issn><gtr:outcomeId>587de327715a07.55260781</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFDF2D42-64D7-4AF1-9A07-DE8CB3EF45A8</gtr:id><gtr:title>A menu-driven facility for sample-size calculation in multiarm, multistage randomized controlled trials with time-to-event outcomes: Update</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5cb7c3f6f4f4b1062f1b9784e9dd4ae"><gtr:id>f5cb7c3f6f4f4b1062f1b9784e9dd4ae</gtr:id><gtr:otherNames>Bratton Daniel J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>587de328ce9b21.42294887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41553C77-B3AE-40DC-9659-678FE5FA0374</gtr:id><gtr:title>How do you design randomised trials for smaller populations? A framework.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>585d3c86464ec2.52960332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>047EA9E5-B33D-4ABF-9A99-0A8A6D0DE0BF</gtr:id><gtr:title>Improving upon the efficiency of complete case analysis when covariates are MNAR.</gtr:title><gtr:parentPublicationTitle>Biostatistics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c34e94bd25d0c4d84818d65e5b6d975"><gtr:id>2c34e94bd25d0c4d84818d65e5b6d975</gtr:id><gtr:otherNames>Bartlett JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-4644</gtr:issn><gtr:outcomeId>545a203a0cca16.53908584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD482098-A0D4-4630-94D0-435788BD7EE4</gtr:id><gtr:title>Recent heterosexual partnerships and patterns of condom use: a weighted analysis.</gtr:title><gtr:parentPublicationTitle>Epidemiology (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af5840e7bd12264ce3141ce9d41bd11"><gtr:id>1af5840e7bd12264ce3141ce9d41bd11</gtr:id><gtr:otherNames>Copas AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1044-3983</gtr:issn><gtr:outcomeId>TPyJt5jMchL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708EF17B-2C08-4680-A804-7B11F347B7CA</gtr:id><gtr:title>A synthesis of convenience survey and other data to estimate undiagnosed HIV infection among men who have sex with men in England and Wales.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/479c53194f9019dc94c5dcbe277a9129"><gtr:id>479c53194f9019dc94c5dcbe277a9129</gtr:id><gtr:otherNames>Walker K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>bGKwkmnCA7z</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DB6A89C-DA0D-49EA-A218-E5E0D21B3EAD</gtr:id><gtr:title>The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13787_27_22540678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BE90715-28F6-4EF0-B5A0-DB6591594274</gtr:id><gtr:title>Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded55b189099956a0ac27e9da424f376"><gtr:id>ded55b189099956a0ac27e9da424f376</gtr:id><gtr:otherNames>Bower P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5447c5aa0b71d4.06459309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50E5C47A-C22B-4AD7-AC68-777C7C38E53C</gtr:id><gtr:title>Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>CEw64YZ67ge</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B230E1AB-2D30-474C-AFC2-B86FC047D14C</gtr:id><gtr:title>Bias in randomised factorial trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23733397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D091323-A972-47D9-AE22-C2395B415400</gtr:id><gtr:title>Evaluation of two-fold fully conditional specification multiple imputation for longitudinal electronic health record data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c0a116c2daaeaf0aa9956e53c0d5e2"><gtr:id>98c0a116c2daaeaf0aa9956e53c0d5e2</gtr:id><gtr:otherNames>Welch CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545a21454cd274.34283948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E916DCC-36FA-4DFF-AD5F-C11F45DA7A15</gtr:id><gtr:title>Combining multiple imputation and inverse-probability weighting.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ddaa0a8b3f093f80e3577c6ca6033bfb"><gtr:id>ddaa0a8b3f093f80e3577c6ca6033bfb</gtr:id><gtr:otherNames>Seaman SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>n42Xdy4ZJSV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C35AABC5-B4F5-4E85-93D7-2433FE74BD8A</gtr:id><gtr:title>External validation of a Cox prognostic model: principles and methods.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_13787_27_23496923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A212145-5156-45D3-AA8A-8B732311D6D8</gtr:id><gtr:title>An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>54579117d62dd3.08226297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72B2B99D-FF50-4CBE-8E68-E88D48469FC0</gtr:id><gtr:title>Multiple imputation using chained equations: Issues and guidance for practice.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bd522716636d6c40c2c616ae992e297"><gtr:id>9bd522716636d6c40c2c616ae992e297</gtr:id><gtr:otherNames>White IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>omU8AzF7o82</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60348DBE-05E4-422A-B543-CF184C0D9C10</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58b98f57a1f775.39638054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD679C2-85C0-491B-B10F-819488990D43</gtr:id><gtr:title>Designing phase II trials in cancer: a systematic review and guidance.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30c43e6840b8f105412d699669faa15c"><gtr:id>30c43e6840b8f105412d699669faa15c</gtr:id><gtr:otherNames>Brown SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>an5UPHg3Rfs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F8A495F-F9F1-436E-95FD-7FB8D4A36DFD</gtr:id><gtr:title>Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_13787_27_22983531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EABC8425-5999-411D-917F-124DBA680088</gtr:id><gtr:title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d98c29beb6dc28d0f861418f49d65494"><gtr:id>d98c29beb6dc28d0f861418f49d65494</gtr:id><gtr:otherNames>Ahmed H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b98c09ba4404.16448606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CA81263-1441-439B-891A-6BF8B41DFE59</gtr:id><gtr:title>Bias from the use of generalized estimating equations to analyze incomplete longitudinal binary data</gtr:title><gtr:parentPublicationTitle>Journal of Applied Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e978339e71cb30f39d9260c7ce5c8139"><gtr:id>e978339e71cb30f39d9260c7ce5c8139</gtr:id><gtr:otherNames>Copas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>spVa2d9JKQL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6835BE97-6F1D-46CD-A8D2-EED20E657634</gtr:id><gtr:title>The epidemiology and treatment of mesothelioma in South East England 1985-2002.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf3f019280370bf81a651628d8dbc856"><gtr:id>bf3f019280370bf81a651628d8dbc856</gtr:id><gtr:otherNames>Mak V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>587de326e12b09.00649751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5975211F-64B9-48F3-809C-C9B11323A1D1</gtr:id><gtr:title>Future research and methodological approaches.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f184b6ed8760ce6369636e3471e7700"><gtr:id>7f184b6ed8760ce6369636e3471e7700</gtr:id><gtr:otherNames>Pater J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>LYtGFRVaqEf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C827DEC-624C-49C1-8E47-3190FCCAE31E</gtr:id><gtr:title>Investigation of continuous effect modifiers in a meta-analysis on higher versus lower PEEP in patients requiring mechanical ventilation--protocol of the ICEM study.</gtr:title><gtr:parentPublicationTitle>Systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21db4be6be9922719db88a73aa2562d5"><gtr:id>21db4be6be9922719db88a73aa2562d5</gtr:id><gtr:otherNames>Kasenda B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2046-4053</gtr:issn><gtr:outcomeId>54579217ad1ad0.23419335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB2A7A0E-DB0A-44DB-A30E-994B5E9BA410</gtr:id><gtr:title>Two-stage meta-analysis of survival data from individual participants using percentile ratios.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68e615d9c2624ac665554735c88462e"><gtr:id>f68e615d9c2624ac665554735c88462e</gtr:id><gtr:otherNames>Barrett JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_22825835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E71F6AFD-3306-4BC0-B935-0364EA2AF44F</gtr:id><gtr:title>Multiple imputation for an incomplete covariate that is a ratio.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b1d9399bd3eb60d72d90806cff36fc5"><gtr:id>0b1d9399bd3eb60d72d90806cff36fc5</gtr:id><gtr:otherNames>Morris TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_23922236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>948345E1-4D52-4168-9E91-968342141343</gtr:id><gtr:title>Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0273dd103e257f1782539313e806d79c"><gtr:id>0273dd103e257f1782539313e806d79c</gtr:id><gtr:otherNames>Cozzi-Lepri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>KNcpMxHV9nz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FA77CA3-EB99-43BB-8781-5D702F20DF06</gtr:id><gtr:title>Socio-economic inequalities in testicular cancer survival within two clinical studies.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800475c0904d0fb21ccc89924e4f82d1"><gtr:id>800475c0904d0fb21ccc89924e4f82d1</gtr:id><gtr:otherNames>Nur U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1877-7821</gtr:issn><gtr:outcomeId>pm_13787_27_21890445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96CC2457-88E0-47A7-8A7B-345071544D19</gtr:id><gtr:title>Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2-3 randomised trial</gtr:title><gtr:parentPublicationTitle>The Lancet Gastroenterology &amp; Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8fc7aab55825204e4ea4a91d8c76fa9"><gtr:id>f8fc7aab55825204e4ea4a91d8c76fa9</gtr:id><gtr:otherNames>Adams R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a999e37241945.08840660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED770256-D2BB-48C8-ACEA-048A50089FB2</gtr:id><gtr:title>Review of methods for handling confounding by cluster and informative cluster size in clustered data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f1b750c0be9196a7289341d97f2526d"><gtr:id>4f1b750c0be9196a7289341d97f2526d</gtr:id><gtr:otherNames>Seaman S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545791180daf82.93999910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99C3AAB0-10C7-4440-B504-C5CC519611CA</gtr:id><gtr:title>Avoiding bias due to perfect prediction in multiple imputation of incomplete categorical variables.</gtr:title><gtr:parentPublicationTitle>Computational statistics &amp; data analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bd522716636d6c40c2c616ae992e297"><gtr:id>9bd522716636d6c40c2c616ae992e297</gtr:id><gtr:otherNames>White IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0167-9473</gtr:issn><gtr:outcomeId>rTgSo7YcHqc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15DC28F5-07EA-4CF8-AEDF-777EECABA780</gtr:id><gtr:title>An ethnographic study of group decision making to understand and improve how trial steering committees contribute to trial conduct</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92f3c66fa53b6ec7c71818d337ada01"><gtr:id>c92f3c66fa53b6ec7c71818d337ada01</gtr:id><gtr:otherNames>Daykin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5459fada038270.44292537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E3C8116-2B20-47E8-9AB5-E58D193EE7EC</gtr:id><gtr:title>Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ebf169d9f9376e24723f13c155e417b"><gtr:id>9ebf169d9f9376e24723f13c155e417b</gtr:id><gtr:otherNames>Brueton VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>54579300238ea7.60046921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF0777D4-D179-4C34-B361-03DA68753C23</gtr:id><gtr:title>A systematic search for reports of site monitoring technique comparisons in clinical trials.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e1077d636c52e376f9019b05aa367e2"><gtr:id>1e1077d636c52e376f9019b05aa367e2</gtr:id><gtr:otherNames>Bakobaki J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>VSaBB3BpVns</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04A0A30D-11F3-4D1B-B400-0D9A8809FC56</gtr:id><gtr:title>Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved.</gtr:title><gtr:parentPublicationTitle>European journal of heart failure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c880c934fa79f1772bcc1713e6f633df"><gtr:id>c880c934fa79f1772bcc1713e6f633df</gtr:id><gtr:otherNames>Rogers JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1388-9842</gtr:issn><gtr:outcomeId>545ba450a8b368.60121729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFBE3919-FD32-4FD2-8FCD-9186B64AA6AC</gtr:id><gtr:title>Development and validation of a prediction model with missing predictor data: a practical approach.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0060ce097f56408737cf013657f5ff94"><gtr:id>0060ce097f56408737cf013657f5ff94</gtr:id><gtr:otherNames>Vergouwe Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>MdJj2nduzkX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14F528A3-916E-4016-8CA8-A9B9D61BE1D0</gtr:id><gtr:title>Prognosis and prognostic research: validating a prognostic model.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/123180a0ea2667ab113a42cbe9d3b2e9"><gtr:id>123180a0ea2667ab113a42cbe9d3b2e9</gtr:id><gtr:otherNames>Altman DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>bNKozU3ATZY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D7D8668-C8C7-4F6A-A8C6-41E9C0654A59</gtr:id><gtr:title>More multiarm randomised trials of superiority are needed.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5457b91932ce02.21669672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE32D1BF-B2A1-4D00-AA0F-F0745E56EBC2</gtr:id><gtr:title>Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a90b45f679d889fd75b95b5af0f57380"><gtr:id>a90b45f679d889fd75b95b5af0f57380</gtr:id><gtr:otherNames>Wittkop L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>iXLb1pgSDEq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1904AE7-F614-4107-837E-5551F78C5A98</gtr:id><gtr:title>Joint modelling rationale for chained equations.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b18ef1bb71f9d1c5b2422991e2bebc17"><gtr:id>b18ef1bb71f9d1c5b2422991e2bebc17</gtr:id><gtr:otherNames>Hughes RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>545a20a430e8d3.45807178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADED45F6-A965-42C0-9A04-B7C1AA5E34D2</gtr:id><gtr:title>Alternative approaches to tuberculosis treatment evaluation: the role of pragmatic trials.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>XSeG45TUvmg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3EF6804-18F3-4F2B-94B1-AF9B701B7FBB</gtr:id><gtr:title>Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>54579071a3a358.48523626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52C42B64-853E-423C-ACFB-37979F6A4513</gtr:id><gtr:title>Potential pitfalls in the design and reporting of clinical trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>Nynj5K8ouen</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D86FD2EB-A72F-4643-BFA6-D5F8CEF03602</gtr:id><gtr:title>STRengthening analytical thinking for observational studies: the STRATOS initiative.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f1cb68f57735ad7d7c5ab8416345efc"><gtr:id>2f1cb68f57735ad7d7c5ab8416345efc</gtr:id><gtr:otherNames>Sauerbrei W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545a217c4f0d06.66127334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E924CEF-A150-4116-A2F9-A4D4675A3131</gtr:id><gtr:title>One-stage parametric meta-analysis of time-to-event outcomes.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8673d4fbac0d38f966b6ad3c6ec647ba"><gtr:id>8673d4fbac0d38f966b6ad3c6ec647ba</gtr:id><gtr:otherNames>Siannis F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>MHRwBsS7GvN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E810E8D-DF46-473E-9884-2917E39ABD56</gtr:id><gtr:title>Prognosis and prognostic research: what, why, and how?</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea46aa157f53303836291b13e8e0a302"><gtr:id>ea46aa157f53303836291b13e8e0a302</gtr:id><gtr:otherNames>Moons KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>eUg3taPPrgh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D04D4C1A-F0EA-442A-8B19-4C2124DFA716</gtr:id><gtr:title>Improper analysis of trials randomised using stratified blocks or minimisation.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13787_27_22139891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD1FD859-58EE-41A1-BE48-E33629345CA5</gtr:id><gtr:title>Multiple Imputation by Chained Equations (MICE): Implementation in Stata</gtr:title><gtr:parentPublicationTitle>JOURNAL OF STATISTICAL SOFTWARE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1548-7660</gtr:issn><gtr:outcomeId>ToeP7TvSH6R</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4864563-DE80-4CA6-BDD4-1EDA36531170</gtr:id><gtr:title>Use of strategies to improve retention in primary care randomised trials: a qualitative study with in-depth interviews.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ebf169d9f9376e24723f13c155e417b"><gtr:id>9ebf169d9f9376e24723f13c155e417b</gtr:id><gtr:otherNames>Brueton VC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545793009fb3d3.78644529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A38FFF1-FDBA-4B98-ACEF-788F4052422C</gtr:id><gtr:title>The need for a cultural shift from two-arm to multi-arm RCTS</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4daa1d84649c844f7c158f9a4015f86f"><gtr:id>4daa1d84649c844f7c158f9a4015f86f</gtr:id><gtr:otherNames>Sydes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5459fe71a067a6.06264647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1F683CE-AC39-44F0-BF40-2C6D3F3B3E69</gtr:id><gtr:title>Estimating the crude probability of death due to cancer and other causes using relative survival models.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/911e4358932afc9a1c7ab191e7a89810"><gtr:id>911e4358932afc9a1c7ab191e7a89810</gtr:id><gtr:otherNames>Lambert PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>MhYSqsCFRfa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A207C58A-4EC1-4260-818B-E66726B18464</gtr:id><gtr:title>Data linkage reduces loss to follow-up in an observational HIV cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/714c11cae3bdf9319cae1a059307588e"><gtr:id>714c11cae3bdf9319cae1a059307588e</gtr:id><gtr:otherNames>Hill T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>Jav6C4GZQFC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55D5313B-740E-436B-95CB-75AEB578521F</gtr:id><gtr:title>External validation of a prognostic model for seizure recurrence following a first unprovoked seizure and implications for driving.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98f47ea97497d37864b4cacd71d1aced"><gtr:id>98f47ea97497d37864b4cacd71d1aced</gtr:id><gtr:otherNames>Bonnett LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56cc4b8b3c5f06.23335637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12367459-41A2-4B93-B190-8738DD5BC957</gtr:id><gtr:title>A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb9dad56c309450cfd152f19ba8862e0"><gtr:id>bb9dad56c309450cfd152f19ba8862e0</gtr:id><gtr:otherNames>Fisher DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>UmLiDEXCnEo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B811363E-A0CA-4B8B-96D3-804D8F25FFB5</gtr:id><gtr:title>Two-stage nonparametric bootstrap sampling with shrinkage correction for clustered data</gtr:title><gtr:parentPublicationTitle>The Stata Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6c7421429a6a04005f890712fcd6b0d"><gtr:id>d6c7421429a6a04005f890712fcd6b0d</gtr:id><gtr:otherNames>Ng E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>GGA91YFR9pJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F593FEAC-9F6D-43D4-8336-BF99F6A41741</gtr:id><gtr:title>Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea46aa157f53303836291b13e8e0a302"><gtr:id>ea46aa157f53303836291b13e8e0a302</gtr:id><gtr:otherNames>Moons KG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>pm_13787_27_22397945</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9100BE9C-277C-4CF1-84F2-86CAB862F5E8</gtr:id><gtr:title>Reporting performance of prognostic models in cancer: a review.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/576b14cff8e7d733fb1225b563732a59"><gtr:id>576b14cff8e7d733fb1225b563732a59</gtr:id><gtr:otherNames>Mallett S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>SWLti9QfYg2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69FCF53F-3CB3-43C8-8553-1CEE67665B30</gtr:id><gtr:title>The impact of the 0-0 cell on measures of amino acid covariation.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>KZapMFTcfBY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41882036-7A67-4CE0-92EE-FBAA01EE6A02</gtr:id><gtr:title>A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>5457b455b47346.37359735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>830711EC-3C51-4EDC-9435-2568801DE004</gtr:id><gtr:title>Comparison of random forest and parametric imputation models for imputing missing data using MICE: a CALIBER study.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb1d80c3159b9d9692bb3652348af076"><gtr:id>bb1d80c3159b9d9692bb3652348af076</gtr:id><gtr:otherNames>Shah AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>545a20da1bc939.34880795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83D084F3-E0B5-4282-B1A6-8A196DF90306</gtr:id><gtr:title>Relaxing the independent censoring assumption in the Cox proportional hazards model using multiple imputation.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cab0d53161368150e28f9caa0627018"><gtr:id>9cab0d53161368150e28f9caa0627018</gtr:id><gtr:otherNames>Jackson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545a21ae4d8bd0.79757074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3745DAE4-CD26-4E44-8D6F-499ED818E12F</gtr:id><gtr:title>Tuning multiple imputation by predictive mean matching and local residual draws.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b1d9399bd3eb60d72d90806cff36fc5"><gtr:id>0b1d9399bd3eb60d72d90806cff36fc5</gtr:id><gtr:otherNames>Morris TP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>545792185cc717.46539081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B6AA95D-8870-464F-B863-091D82698054</gtr:id><gtr:title>Prognosis and prognostic research: Developing a prognostic model.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>AL7aguTbd2g</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFD1304D-C7D0-4F48-88AF-D4C0E00B160C</gtr:id><gtr:title>How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b14c3c3b7664e5778907415a8ced5c96"><gtr:id>b14c3c3b7664e5778907415a8ced5c96</gtr:id><gtr:otherNames>Barthel FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>nKW4C27kcbA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB0EF852-987D-48D9-B757-6C64E5F3A5DF</gtr:id><gtr:title>Fitting multilevel multivariate models with missing data in responses and covariates that may include interactions and non-linear terms</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Statistical Society: Series A (Statistics in Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea862530972faafe0117622af06cb8fb"><gtr:id>ea862530972faafe0117622af06cb8fb</gtr:id><gtr:otherNames>Goldstein H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a20033af368.92314380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B73AAC8-73B8-4618-930E-F789D6114BDF</gtr:id><gtr:title>Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).</gtr:title><gtr:parentPublicationTitle>JACC. Heart failure</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c880c934fa79f1772bcc1713e6f633df"><gtr:id>c880c934fa79f1772bcc1713e6f633df</gtr:id><gtr:otherNames>Rogers JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-1779</gtr:issn><gtr:outcomeId>545ba491ef5b69.99714934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C43C3CE-4AC4-4538-984D-1F19B6564E59</gtr:id><gtr:title>Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>56cc52f115ecf7.90030466</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>484B9DF2-2095-46EC-9367-6283DC69868A</gtr:id><gtr:title>A note regarding 'random effects' - authors' response.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3be87a0349e771320cc97b387ef3dc7a"><gtr:id>3be87a0349e771320cc97b387ef3dc7a</gtr:id><gtr:otherNames>Kahan BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5457b14d685da4.98849743</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7939FE6C-E410-42BA-B410-A00F81DA0E80</gtr:id><gtr:title>Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d53b218500ae8d4b2ed732abfeb2ee1"><gtr:id>7d53b218500ae8d4b2ed732abfeb2ee1</gtr:id><gtr:otherNames>Faria R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5a9a999e524e11.79609928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8A50A23-4CCC-4AD7-8B1A-30986CFE9551</gtr:id><gtr:title>Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/593393822da26709697a3e72eafc6de5"><gtr:id>593393822da26709697a3e72eafc6de5</gtr:id><gtr:otherNames>Stark DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>5a9aa639c99e09.74193633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33CA1F42-3AE6-42CA-BEA6-6DAB302B255E</gtr:id><gtr:title>An examination of a method for marginal inference when the cluster size is informative</gtr:title><gtr:parentPublicationTitle>Statistica Sinica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6365df7a557bdc44a76db0ed34503fe"><gtr:id>b6365df7a557bdc44a76db0ed34503fe</gtr:id><gtr:otherNames>Pavlou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>fmATXpPohEY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3648804-BE0D-44EB-B971-1AEBD71B0551</gtr:id><gtr:title>Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d23ceb7e3c56afc2a019d40d709e8c11"><gtr:id>d23ceb7e3c56afc2a019d40d709e8c11</gtr:id><gtr:otherNames>Choodari-Oskooei B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13787_27_23343147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC30A59D-44A5-41F6-B543-298641DCAF7A</gtr:id><gtr:title>Multiple imputation of missing values: New features for mim</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>jWkro7aergi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E64C0F9-C81B-4FEE-B19C-7544306BFB1F</gtr:id><gtr:title>Doubly robust generalized estimating equations for longitudinal data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f1b750c0be9196a7289341d97f2526d"><gtr:id>4f1b750c0be9196a7289341d97f2526d</gtr:id><gtr:otherNames>Seaman S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>Fw5aRqynZ62</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10AF3CFE-F33F-41F6-802A-BA0DFB6EFAB3</gtr:id><gtr:title>When inferiority meets non-inferiority: implications for interim analyses.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3088bd154652a88684085b596cb8ca47"><gtr:id>3088bd154652a88684085b596cb8ca47</gtr:id><gtr:otherNames>Bratton DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>pm_13787_27_22796636</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAD8D287-CC9D-42B0-A2F2-E22482934A51</gtr:id><gtr:title>Multiple imputation of missing values: Further update of ice, with an emphasis an categorical variables</gtr:title><gtr:parentPublicationTitle>STATA JOURNAL</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a7082a813f9073c58907b3ad409ebbe"><gtr:id>9a7082a813f9073c58907b3ad409ebbe</gtr:id><gtr:otherNames>Royston Patrick</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1536-867X</gtr:issn><gtr:outcomeId>PrsA5FrnDTB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FF75DD4-E047-4CF9-8EE8-FD2CC0BDBD4D</gtr:id><gtr:title>Royston P. A smooth covariate rank transformation for use in regression models with a sigmoid dose-response function.</gtr:title><gtr:parentPublicationTitle>The Stata Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d52cfc0ce641dd5899c5482937339da6"><gtr:id>d52cfc0ce641dd5899c5482937339da6</gtr:id><gtr:otherNames>Royston P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5457b3278f0726.84965015</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE3A5CBD-5F2E-4B84-89BF-E938049FF503</gtr:id><gtr:title>Can we deliver randomized trials of focal therapy in prostate cancer?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>5457b9195cb180.78357744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECA8D8FF-858D-43A7-8F1F-FC118D19C0AE</gtr:id><gtr:title>Involvement of consumers in studies run by the Medical Research Council Clinical Trials Unit: results of a survey.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13787_27_22243649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0431FD7-09D7-4644-A6FC-A6E2052EB7BE</gtr:id><gtr:title>A simulation study of predictive ability measures in a survival model I: explained variation measures.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d23ceb7e3c56afc2a019d40d709e8c11"><gtr:id>d23ceb7e3c56afc2a019d40d709e8c11</gtr:id><gtr:otherNames>Choodari-Oskooei B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>e8b7ixTnebq</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_G0800814</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>